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Abstract 
Age-related macular degeneration (AMD) is the leading cause of visual impairment in 
the UK. In 2005, the first publication of a genome-wide associated study identified a 
single nucleotide polymorphism in complement factor H (CFH) as a genetic risk factor 
for AMD. CFH is a secreted regulator of the alternative complement pathway and 
therefore key to controlling the inflammatory response.  Prior to 2005, little was 
known about the role of CFH in the retina. This study addresses this question in order 
to understand how this protein could contribute towards AMD pathology. 
 
Initial experiments confirmed that retinal pigment epithelial (RPE) cells are capable of 
secreting detectable levels of CFH, and that RPE cells were able to enhance the 
secretion of CFH in response to inflammatory stimuli. The main focus of this study was 
to characterise the effect of loss of CFH on young and aged retina in Cfh-/- mice. 
Immunohistochemical studies revealed that signs of stress and re-distribution of 
complement proteins appear at one year of age. Genome-wide microarray analysis of 
the RPE and choroid or neuroretina, showed that loss of CFH has little effect on gene 
expression in young mice but that the impact of CFH loss increases with age.  The 
largest group of genes to change were involved in antigen presentation and immunity 
suggesting that CFH has an important role in immune regulation in the eye. 
 
Analysis of visual function using electoretinograms revealed that dysfunction seen at 
two years was not present at one year, indicating that age-related gene expression 
changes are likely to be involved in the pathogenic process in these mice. This study 
reveals the importance of CFH in maintaining retinal health and good visual function 
with age. 
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Chapter 1: Introduction 
1.1. The complement system 
The sophisticated complement system, present in mammals today, acts as the 
frontline defence against invading pathogens. Additionally, it facilitates the removal of 
modified and dead host cells. This system has evolved within multicellular organisms 
over millions of years with the earliest homologs dating back to 550 million years ago 
in the horseshoe crab, Carcinoscorpius rotundicauda (Zhu et al., 2005). Family 
members share conserved structural motifs and domains indicative of evolutionary 
multiple exon shuffling and gene duplication.  
 
The complement system in mammals consists of over 30 soluble and membrane bound 
proteins which either act as activators, regulators or receptors of innate immunity. The 
proteins work together to discriminate pathogens and modified self from normal host 
cells and initiate their removal whilst protecting neighbouring host cells. This is done 
through the recognition of pathogen or host-associated molecular patterns (P- and 
HAMPs). Identification of a pathogen or modified self causes activation of a cascade 
whereby the activating components sequentially cleave each other leading to several 
effector functions that initiate the pathogen’s removal. The cascade style response is 
biologically beneficial as it allows rapid amplification when a fast response is 
necessary. Moreover, the cascade can be regulated at each level so to have increased 
control over the immune response and to make it appropriate to the level required for 
the initiating stimulus.  
 
Paul Ehrlich coined the term, ‘complement system’ in the late 1890s to describe the 
complementary action of the heat labile proteins in serum to that of specific heat 
stable proteins (now known to be antibodies). Originally complement was thought only 
to assist the function of antibodies, however in the 1930s complement’s independent 
role in the innate recognition of microbes was described. Over recent years it has 
emerged that complement also plays a key role in adaptive immunity and immune 
homeostasis. It is also important in the removal of cellular debris such as apoptosed 
cells and immune complexes.  
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1.1.1. The complement system 
The activators of the complement system are a collection of inactive proteases 
(zymogens) which require cleavage to become active. There are three activation 
pathways of these zymogens which make up the complement system: the classical, 
lectin and alternative (Figure 1.1). Each pathway has its own mechanism that enables it 
to distinguish between foreign and host cells. Between these three activation 
pathways a huge range of PAMPs can initiate activation of the system. 
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The classical pathway is unique in that it bridges the innate and adaptive immune 
systems. The initiator of the pathway is C1 which is made up of three subunits, C1q, 
C1r and C1s. These subunits come together upon activation, which relies heavily upon 
antigen-antibody (Immunoglobulin (Ig) M or IgG1 and IgG3) complexes. In addition C1q 
can bind PAMPs present on microbes (Mintz et al., 1995), pentraxins (Nauta et al., 
2003), deoxyribonucleic acid (DNA) (Garlatti et al., 2010), polyanionic molecules and 
apoptotic bodies (Korb and Ahearn, 1997). Activation causes cleavage of C1r and C1s 
exposing protease activity which goes on to cleave C4 and C2, generating the smaller 
fragments C4a and C2b. The larger C4 fragment, C4b, binds covalently to target 
surfaces. The larger C2 fragment, C2a, binds C4b on target surfaces to form the 
enzymatic complex C3 convertase, C4b2a. 
 
In the lectin pathway, collectins (mannose-binding lectin (MBL), L-, H- or M-ficolin) 
associate with MBL-associated serine proteases (MASPs). The collectins have many 
binding sites and together have a broad specificity for terminal carbohydrates on 
microbial glycoproteins. Once collectins bind to a PAMP, associated MASPs become 
activated and cleave C4 and C2 in the same manner as the classical pathway.  
 
The alternative pathway of complement activation is different in that it is constantly 
active at a low level by the tick-over pathway. In this pathway C3 is continually 
hydrolysed by water into C3(H2O) in the serum (Lachmann and Halbwachs, 1975). An 
exposed thioester group in C3(H2O) can bind to the inactive serine protease, Factor B. 
Factor B is subsequently cleaved by Factor D releasing a small fragment Ba and 
revealing the active serine protease site in the larger Bb fragment. C3(H2O)Bb acts as a 
fluid phase C3 convertase, converting C3 to C3a and C3b.  
 
The generation of C3b is the key step to amplifying the tick-over pathway for full-
blown activation. At this step, regulators of the pathway mop up free C3b preventing 
full-blown activation. Unlike the other two pathways, the discrimination between host 
and pathogen comes from the regulators rather than the activators. Complement 
factor H (CFH) recognises HAMPs such as glycosaminoglycans present on the surface of 
host cells. C3b can only activate the cascade if bound to a surface which is unprotected 
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by regulators such as CFH or its membrane bound homologues (see Section 1.1.3). C3b 
like C3(H2O) binds Factor B and is cleaved by Factor D to form C3bBb. C3bBb is an 
active C3 convertase with twice the convertase activity of C3(H2O)Bb and can 
therefore amplify the tick-over pathway (Bexborn et al., 2008). 
 
C3 convertase is stabilised by association with the soluble protein properdin which 
increases its half-life tenfold (Fearon and Austen, 1975). More recently it has emerged 
that properdin can initiate activation of the alternative pathway by recruiting serum 
C3b as a platform for C3 convertase formation. Properdin has been shown to direct 
C3b towards apoptotic and necrotic cells, and also pathogens through its PAMP 
recognition ability (Spitzer et al., 2007). The alternative pathway can also become 
activated in response to lectin or classical pathway activation, since both drive the 
formation of C3b. Once C3b concentrations outweigh the balance kept by regulators, 
alternative pathway activation can proceed. To add to the complexity of this cascade 
new evidence suggests there may be several bypass pathways which are capable of 
activating the cascade in the absence of key components (Huber-Lang et al., 2006). 
 
1.1.2. Complement effector functions 
All pathways, although activated by different molecules, converge in the formation of 
the central complement enzyme, C3 convertase, and from this point all pathways lead 
to the same downstream effects. C3 convertase causes the breakdown of C3 whose 
products in turn allow the formation of C5 convertase (C4b2a3b or C3b2Bb) which 
releases further pro-inflammatory proteins. The result of complement activation is the 
initiation of pathogen, apoptotic cell and immune complex clearance. This is achieved 
in three ways. Firstly, the small break down products, C3a, C4a and C5a act as pro-
inflammatory anaphylatoxins which attract leucocytes expressing chemokine 
receptors. Anaphylatoxins enhance this process by acting on endothelial cells to 
increase vascular permeability (Schraufstatter et al., 2002). Once recruited, mast cells, 
granulocytes and macrophages are activated by C3a and C5a (Klos et al., 2009).  
 
Secondly, opsonins C3b, iC3b, C3d, C3dg and C4b which are released by enzymatic 
cleavages, covalently bind to amino and hydroxyl groups on the surface of cells and 
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basement membranes via an active thioester. Although opsonins cannot discriminate 
between host and pathogen surfaces, C3b has been shown to preferentially bind 
microbial carbohydrates (Sahu et al., 1994). Opsonins target the attracted leucocytes 
to pathogens to enhance their clearance. Complement receptors (CR) 1, 3 and 4 
mediate phagocytosis through C3 fragment recognition. C3b and C3d also stimulate 
antigen uptake for processing by professional antigen presenting cells by binding to 
the B-cell receptor and CR2 (Dempsey et al., 1996). C3b coated pathogens can also be 
cleared by binding to CR1 receptors on red blood cells which transport pathogens to 
phagocytes in the liver and spleen in a process called immune adherence (Nelson, Jr., 
1953).  
 
Finally, complement can directly clear pathogens by the formation of membrane 
attack complex (MAC). MAC formation is the terminal part of the cascade where C5b 
released upon C5 cleavage by C5 convertase binds to C6 and C7 in their fluid phase, 
this complex attaches to the surface of cells and forms a pore with C8 and multiple 
molecules of C9. C9 is able to penetrate the lipid bilayer of the cell envelope where it 
polymerises to create pores. Multiple pores disrupt membrane integrity and can cause 
cell lysis. Sublytic levels of MAC are also able to promote inflammation by inducing 
functional changes in host cells (work published from our group, Lueck et al., 2011). 
 
In summary the main effector functions of the complement cascade are the generation 
of inflammatory mediators, anaphylactic peptides, cytolytic and antimicrobial 
compounds and the recruitment of leucocytes. Unlike the adaptive immune system, 
the complement system can act very fast, and within five minutes of activation, C3b 
opsonisation is maximal with 20 million molecules deposited per target cell (Ollert et 
al., 1994). 
 
1.1.3. Complement regulation 
The complement cascade is tightly regulated in order to determine the level and 
length of the amplification which is appropriate for clearance of the target. A 
proportionate and targeted defence prevents unnecessary amplification and bystander 
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damage of host cells.  Proteins which regulate the pathway target one of the four main 
stages of the cascade:  
 
1. Activation of the pathway  
2. C3 convertase formation, decay and by-product degradation 
3. C5 convertase formation , decay and by-product degradation 
4. MAC assembly and function 
 
As is the nature of a cascade, regulators which target components earlier in the 
cascade indirectly inhibit the formation of components further down the cascade. The 
first level of regulation is preventing activation of the cascade by regulating either the 
classical or lectin pathways (the alternative pathway is constantly active). The soluble 
serpin peptidase inhibitor clade G member 1 (SERPING1) regulates activation of both 
the classical and lectin pathways by blocking serine protease function in C1r, C1s and 
MASP2 (Cicardi et al., 2005). Both MBL/ficolin associated protein-1 (MAP-1) and small 
MBL associated protein (sMAP) regulate activation of the lectin pathway by competing 
with MASPs for binding to MBL or ficolins (Degn et al., 2010). Complement regulators 
which sequester C3b, inhibit the amplification of the tick-over pathway into full blown 
alternative pathway activation, these include CFH, factor H-like 1 (FHL-1) (Zipfel et al., 
1999), CR1, membrane co-factor protein (MCP) and complement receptor of the 
immunoglobulin superfamily (CRIg) (Wiesmann et al., 2006). 
 
The major class of inhibitors act at the level of the C3 convertase which indirectly 
prevents the formation of C5 convertase. By sequestering the proteins the complexes 
are composed of, formation of the complex is inhibited (as mentioned above in the 
alternative pathway). The formation of the classical/lectin pathway C3 convertase, 
(C4b2a), is inhibited by C2 receptor inhibitor trispanning (CRIT) which sequesters C2 
(Inal et al., 2005) and blocks its cleavage by C1 complex or MASPs. If C3 convertases 
are able to form, several regulators are able to promote its dissociation. Factor I, in 
association with a co-factor, (CFH, FHL-1, MCP, C4b binding protein (C4BP) or CR1) 
accelerates the decay of all C3 convertases, through cleavage of the alpha chain of C3b 
or C4b (Bokisch et al., 1975). Several regulators accelerate the decay of C3 convertases 
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independent of Factor I. CFH, FHL-1, decay-accelerating factor (DAF), MCP and CR1 
accelerate the decay of C3bBb through the interaction with C3b whereas C4BP and 
CR1 accelerate the decay of C4b2a through interaction with C4b. Generation of C3 
convertase leads to the production of anaphylatoxin C3a which is degraded by 
carboxypeptidase N therefore inhibiting inflammation (Bokisch and Muller-Eberhard, 
1970). 
 
Finally terminal complement regulators regulate C5 convertase formation, its decay, 
degradation of it by-products and MAC assembly. Complement factor H-related 
protein 1 (CFHR1) inhibits the formation of C5 convertase and MAC assembly (Heinen 
et al., 2009) whereas clusterin, vitronectin and membrane inhibitor of reactive lysis 
(CD59, MIRL) inhibit MAC assembly and function only. Carboxypeptidase N in addition 
to degrading C3a can also degrade C5a (Bokisch and Muller-Eberhard, 1970). 
 
Rodents possess another complement regulator which is not expressed in humans, 
complement receptor type-1 related gene Y (CRRY) which has the co-factor and decay 
accelerating properties of MCP and DAF (Molina, 2002). Additionally in mice, the CD59 
gene is duplicated leading to protein expression of both CD59a and CD59b (Harris et 
al., 2003), however, CD59a is the main regulator of MAC formation (Baalasubramanian 
et al., 2004). 
 
Complement regulatory proteins fall into two main categories, those which are 
membrane bound and those which are soluble and are secreted (Table 1.1). Cells are 
protected by expressing the membrane bound regulators and the molecules which 
attract the soluble ones. Biomembranes such as Bruch’s membrane in the eye and the 
glomerular basement membrane in the kidney are dependent on the soluble 
regulators since they do not have the capacity to express the membrane bound 
regulators. 
   
The expression and distribution of complement regulatory proteins differs between 
cell types and from tissue to tissue. Importantly these proteins can become up or 
down-regulated in order to fine tune local needs, for instance during an infection. 
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1.1.4. Complement synthesis  
The majority of complement proteins in the body circulate in the blood. They are 
synthesised in the liver and their secretion is rapidly enhanced in response to tissue 
injury and inflammation and are therefore termed acute phase proteins.  Interleukin-1 
(IL-1), IL-6 and interferon  (IFN ) are the main cytokines shown to stimulate 
transcription of complement genes (Volanakis, 1995). Unlike other acute phase 
proteins, complement proteins are also synthesised in extra-hepatic sites, which are 
more responsive to inflammatory changes than the liver (Volanakis, 1995). A vast array 
of tissues and cell types have been shown to express complement proteins, discussion 
of which is beyond the scope of this introduction, see review by Morgan and Gasque 
(1997). 
 
1.1.5. Complement and disease 
There are several ways in which the complement system can bring about disease: 
1. Inappropriate activation of the complement system caused by ischemia 
reperfusion injury, burns, apoptosis and necrosis. 
2. Extreme activation of the complement system which saturates host defence 
mechanisms such as antibody mediated autoimmunity, immune complex 
disease and sepsis. 
3. Deficiency or mutation in one of the activatory complement proteins causing 
susceptibility to infection. For example, individuals with properdin deficiency 
have a higher susceptibility to Nisseria infections.  
4. Deficiency or mutation in one of the complement proteins leading to a lack of 
host defence for example, atypical haemolytic uraemic syndrome (aHUS), 
paroxysmal nocturnal haemoglobinuria and age-related macular degeneration 
(AMD). 
 
Dysregulated or misdirected complement activation can result in severe pathology in 
several organ systems. The absence of just one complement protein has the ability to 
disrupt the whole cascade resulting in a variety of diseases (Holers, 2008; Carroll and 
Sim, 2011; Degn et al., 2011). More commonly individuals contain polymorphisms 
which affect the function or expression of a complement protein.  
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1.1.6. Ocular complement expression and eye diseases 
Complement is continuously active at a low level in the eye in order to function as a 
front line defence ready to react quickly to an appropriate challenge (Sohn et al., 
2000). However complement is also involved in protecting host tissue from innocent 
bystander destruction. Complement expression is important in both the front and back 
of the eye. The balance between offence and defence is a crucial function of 
complement within the eye and factors which disrupt this balance can cause disease. 
 
Ocular tolerance is an important feature of immune privilege in the eye. To achieve 
this, the anterior chamber uses immune deviation to react to antigens to promote the 
generation of regulatory T-cells and suppress delayed type hypersensitivity.  In the 
anterior chamber iC3b has been shown to be important in inducing tolerance to new 
antigens (Sohn et al., 2003). 
 
The cornea expresses many complement factors which mediate the generation of 
anaphylatoxins and MAC (Mondino and Sumner, 1990; Mondino et al., 1996) to 
defend this exposed tissue from pathogens in the environment. To minimise damage 
to host tissue, the cornea also expresses complement regulators. A loss in expression 
of these complement regulators is believed to contribute towards corneal disease. 
Complement activation is believed to be a contributing factor in ulceration of the 
cornea (Mondino et al., 1978; Cleveland et al., 1983). 
 
Anterior uveitis, the most common form of uveitis, features inflammation of the iris 
and anterior chamber. The inflammation is brought about by an autoimmune response 
to ocular antigens. In a mouse model of the disease, experimental autoimmune 
anterior uveitis (EAAU), Jha et al., (2006a; 2006b) show that complement activation is 
required for disease development and they observe a concomitant upregulation of 
complement regulators. Complement regulation is important to disease development 
since Daf-/- mice develop a more severe phenotype of EAAU (An et al., 2009) whereas 
administration of recombinant CRRY suppresses disease development (Manickam et 
al., 2010). Administration of Factor B antibodies but not C4 antibodies also suppressed 
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EAAU development, suggesting it is the alternative pathway of complement activation 
which is most important for EAAU development (Manickam et al., 2011). 
  
Complement is also an important feature in the health of the retina. Complement 
dysregulation is implicated in AMD. This was first indicated when complement 
activation products were identified in drusen (Mullins et al., 2000; Johnson et al., 
2000). The development of choroidal neovascularisation (CNV), a feature of AMD, has 
been shown in an animal model to be partly dependent on complement activation 
(Bora et al., 2005). Furthermore, administration of recombinant CD59 suppresses CNV 
in these mice (Bora et al., 2010). The involvement of complement in AMD was 
strengthened when in 2005, four separate studies identified the same single 
nucleotide polymorphism (SNP) in a complement regulator, CFH, as a major risk factor 
for AMD (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 
2005). Prior to describing AMD, I will first introduce CFH in more detail. 
 
1.2. Complement factor H 
CFH is a secreted glycoprotein whose main function is to regulate the activation of 
the alternative complement pathway. CFH was first described by Nilsson and 
Mueller-Eberhand in 1965 as the fifth factor of complement which brings 
thermostability to the heat labile complex of complement (Nilsson and Mueller-
Eberhard, 1965). The role of this protein in the complement system has now been 
well characterised. Thus, CFH’s regulatory function is mediated via its interaction 
with glycosaminoglycans present on host surfaces and the cleavage product of C3, 
C3b. CFH regulates the alternative pathway both in fluid phase and on host surfaces 
by three separate actions: 
 
1. Competing with Factor B for binding to C3b thereby impeding the formation 
of C3 convertase. 
2. Accelerating the decay of C3 convertase (C3bBb) through interaction with 
C3b. 
3. Acting as a co-factor for Factor I-mediated degradation of C3b to iC3b. 
  
 
29 
 
1.2.1. CFH structure 
CFH is composed of 1213 amino acids (aa) which after glycosylation forms a 155 kDa 
glycoprotein (Ripoche et al., 1988). The protein consists of 20 short complement 
repeats (SCR) each of which are between 51-62 aa and are connected by a linker 
sequence of 3-8 aa. Each repeat contains four invariant cysteine residues which form 
two disulphide bonds stabilising the folding of the protein into complement control 
modules also known as sushi domains (Interpro database reference: IPR000436). CFH 
has an elongated structure of -pleated sheets which are folded back to bring the N- 
and C-terminal regions into close proximity (Aslam and Perkins, 2001). The crystal 
structure of the full length protein has yet to be elucidated because of its size, 
glycosylation and inter-SCR flexibility. Instead, structures of CFH protein fragments 
have been studied. CFH is a member of a structurally related family of proteins called 
regulators of complement activation which all contain SCR motifs and whose genes are 
located in a cluster on human chromosome 1q31.3-32.2. Members of this family 
include, CFH, CR2, C4BP, DAF, CR1, MCP, CFHR1-3 and CRRY in rodents. 
 
1.2.2. Binding partners of CFH 
CFH is able to regulate the complement pathway by binding C3b. Using surface 
plasmon resonance and deletion mutants in functional assays, several regions of the 
protein have been identified as having C3b binding capacity (Schmidt et al., 2008) 
(Figure 1.2). N-terminal SCR 1-4 was the first C3b binding region to be identified and is 
now well characterised (Gordon et al., 1995). This region confers the co-factor and 
decay accelerating properties of the protein (Wu et al., 2009). Full length CFH has a 
100 fold greater affinity for C3b than SCR 1-4 alone therefore the possibility for 
additional C3b binding sites were hypothesised. Indeed, a second C3b binding region 
was identified in the C-terminal SCRs 19-20 using deletion mutants (Jokiranta et al., 
2000), and exhibits strong binding to C3b. Two other regions, SCR 6-8 (Sharma and 
Pangburn, 1996) and 8-15 (Schmidt et al., 2008) have both been identified as having 
weak C3b binding capability, however the exact locations within these regions are 
disputed. 
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The ability of the alternative complement pathway to distinguish self  from pathogen 
or modified self lies in the capacity of CFH to bind polyanionic molecules such as sialic 
acid, heparan sulphate and other glycosaminoglycans expressed on host cells.  In fact 
the affinity of CFH for C3b is enhanced by the presence of polyanionic structures which 
helps to direct the protection of CFH towards host cell surfaces (Meri and Pangburn, 
1990; Kelly et al., 2010). Two regions of the protein have been identified to bind 
polyanions, SCR 7 in the middle of the protein (Blackmore et al., 1996) and SCR 19-20 
in the C-terminus (Blackmore et al., 1998b). In the retina, recombinant SCR 6-8 
fragments specifically bind heparan sulphate and dermatan sulphate present on 
choroidal vessels, Bruch’s membrane and retinal pigment epithelium (RPE) (Clark et al., 
2010). 
 
 
 
Integral to CFH’s function is its ability to bind simultaneously to both C3b and 
polyanions, and although the structure of this relationship has not been fully 
elucidated, computer modelling suggests that CFH binds one C3b molecule via its two 
terminal C3b binding sites whilst binding polyanionic structures (Morgan et al., 2011). 
 
  
 
31 
 
CFH also has the capacity to self-associate and form oligomers with dimerisation sites 
located in SCR 6-8 and 16-20 (Perkins et al., 1991; Nan et al., 2008b). The functional 
significance of this oligomerisation is not known but this property may play a role in 
aggregation of the protein found in disease-related protein deposits such as drusen. 
Oligomerisation of the protein is influenced by local zinc and copper concentrations 
(Nan et al., 2008a). It is proposed that C3b may be sterically blocked when CFH 
aggregates, however oligomerisation may alternatively maximise the ability of CFH to 
bind both C3b and polyanions simultaneously. 
 
CFH also has binding capacity for c-reactive protein (CRP) (Okemefuna et al., 2010; 
Perkins et al., 2010). CRP is an acute phase protein which circulates in the blood and is 
up-regulated by inflammation. CRP binds to pathogenic surfaces and necrotic cells and 
can activate the classical complement pathway (Mihlan et al., 2011).  CFH has been 
shown to have two regions which bind CRP, SCR 7 and 8-11 (Jarva et al., 1999). Binding 
to CRP has been disputed because of reports showing that CRP binding to CFH requires 
prior denaturation (Hakobyan et al., 2008). However it is also argued that denatured 
CRP is present on necrotic cells and the presence of CFH on necrotic and apoptotic 
cells helps to remove them safely (Mihlan et al., 2009). It has recently been shown that 
CFH binds non-denatured CRP when CRP is at high concentrations such as in times of 
inflammation (Okemefuna et al., 2010). CFH has also been shown to bind annexin 2, 
DNA and histones on apoptotic cells which may limit inflammation during their 
phagocytosis (Leffler et al., 2010). CFH also binds fibromodullin (Sjoberg et al., 2005), a 
constituent of extracellular matrix, and adrenomedullin (Pio et al., 2001; Martinez et 
al., 2003) which is a multifunctional peptide secreted by the RPE with a role in 
inflammation. This enables the protection of acellular host structures such as Bruch’s 
membrane in the eye (Udono et al., 2000).  
 
Finally, microorganisms have evolved to protect themselves from complement attack 
by expressing complement regulator-acquiring surface proteins which bind to proteins 
such as CFH. These include M-protein of Streptococcus pyogenes (Horstmann et al., 
1988; Blackmore et al., 1998a; Kraiczy et al., 2004), OspE (Hellwage et al., 2001), 
BpCRASP-2 (Hartmann et al., 2006), BpCRASP-3 (Kraiczy et al., 2003) of Borrelia 
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burgdoferi, Gpm1p of Candida albicans (Poltermann et al., 2007), Tuf of Pseudomonas 
aeruginosa (Kunert et al., 2007) LfhA of Leptospira interrogans (Verma et al., 2006) and 
factor-H binding protein of Nisseria meningitides (Madico et al., 2006).  
 
1.2.3. CFH synthesis and expression 
The CFH gene is located on chromosome 1 in both humans (1q31.3) and mice (1F). The 
gene contains 22 exons and yields a transcript of 4.1 kb in humans and 4.4 kb in mice. 
The CFH messenger ribonucleic acid (mRNA) is 71% homologous between humans and 
mice in the coding region and the 5' flanking region has 60% identity. The CFH gene is 
located within the CFH related gene cluster which also contains five CFH-related genes, 
CFHR1-5.   
 
In the human gene, three glucocorticoid response elements, two acute phase signals, 
two 3'-5'-cyclic adenosine monophosphate responsive elements, a retinoic acid 
response element and an IFN  activation site have been identified in the promoter 
region (Munoz-Canoves et al., 1990; Ward et al., 1997). Both mouse and human genes 
share a histone H4 transcription factor binding site which is speculated to be involved 
in the IFN  mediated up-regulation of CFH (Vik, 1996). 
 
The majority of plasma CFH is made by the liver in both humans and rodents (Morris et 
al., 1982; Schwaeble et al., 1987; Mandal and Ayyagari, 2006). In humans, CFH plasma 
concentrations range from 120-790 g/ml (Weiler et al., 1976; Charlesworth et al., 
1979; Adinolfi et al., 1981; Sim and DiScipio, 1982). Like other complement factors, 
CFH is also secreted locally by many cell types in distinct tissues including monocytes, 
fibroblasts, endothelial cells, epithelial cells, glomerular mesangial cells, B-cells, 
oligodendrocytes and astrocytes, (Friese et al., 1999).  
 
1.2.4. Factor H-like protein 1 
FHL1 is a splice variant consisting of the first 9 exons of CFH (Estaller et al., 1991). FHL-
1 is therefore a truncated version of CFH that contains SCR 1-7 and four additional 
hydrophobic C-terminal aa. The concentration of FHL-1 in plasma is tenfold lower than 
that of CFH (Kotarsky et al., 1998). Nevertheless, FHL-1 is capable of regulating the 
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alternative complement pathway through binding of C3b in its N-terminus and the 
polyanion binding site in SCR 7 (Misasi et al., 1989).  FHL-1, like CFH is also secreted by 
extra-hepatic sources however studies have revealed that the two proteins have 
tissue-specific differences in their expression and regulation (Friese et al., 1999). 
 
1.2.5. CFH-related proteins  
The CFH related proteins, CFHR1-5, are by implication structurally similar to CFH, in 
that they were first identified using polyclonal antibodies to CFH, but unlike FHL-1 are 
transcribed from different genes (Zipfel and Skerka, 1994). With their structural 
similarities it is unsurprising that their functions suggest roles in complement 
regulation. Indeed, CFHR1 has been shown to regulate C5 convertase activity and MAC 
formation (Heinen et al., 2009) and CFHR5 is capable of regulating C3 convertase 
activity (McRae et al., 2005). CFHR3 and 4 have been shown to have C3b binding 
capacity (Hellwage et al., 1999). 
 
1.2.6. Diseases associated with CFH 
Several CFH mutations have been linked to pathology of the kidney. The kidney is 
particularly vulnerable because of its high exposure to blood and complement 
components within it. Since the glomerular basement membrane does not express 
membrane bound complement regulators, it is dependent on soluble ones for its 
protection. Therefore mutations which affect the function of soluble complement 
regulators often manifest within this organ. 
 
One of the major causes of the childhood kidney disease, aHUS, are mutations in the C-
terminus of CFH which affect the binding of this protein to polyanions, C3b or both 
(Perez-Caballero et al., 2001). This leads to less control over the activation of the 
alternative pathway, the consequences of which manifest first in the kidney where 
most damage occurs. Consistent with this, a mouse which lacks the C-terminal domain 
of CFH develops spontaneous aHUS (Pickering et al., 2007). aHUS can also be caused 
and or exacerbated by mutations in other complement proteins including Factor I, 
Factor B, C3b and MCP (Fremeaux-Bacchi et al., 2008).  
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An aa deletion in the N-terminal C3b binding domain of CFH causes dense deposit 
disease (DDD), (Licht et al., 2006). DDD, is a disease which manifests at the glomerular 
basement membrane of the kidney. This also occurs in Cfh-/- pigs, humans and mice 
(Pickering et al., 2002). Humans with DDD often also develop soft drusen in their eyes, 
an acknowledged risk indicator for AMD, and their composition is similar, suggesting a 
common or similar molecular pathogenesis (D'souza et al., 2009). However, unlike in 
AMD, DDD patients do not exhibit retinal damage. 
 
There have also been reports that Alzheimer’s disease (Zetterberg et al., 2008) and 
myocardial infarction (Kardys et al., 2006) are associated with mutations in CFH, 
however both of these associations have been disputed (Stark et al., 2007; Hamilton et 
al., 2007).  
 
As previously mentioned, a common SNP in CFH is a significant risk factor for AMD. 
This SNP involves a histidine substitution for tyrosine at position 402 of the protein 
(Y402H), within a cluster of positively charged aa in SCR 7. Initially the broad binding 
capacity of this domain, known to bind C3b, CRP and polyanionic molecules, was 
thought to be the disease causing mechanism of this SNP. Although many groups have 
now studied this, a clear answer has yet to be found. It is has been shown that this SNP 
does not affect the secretion of the protein (Yu et al., 2007) nor its affinity to C3b 
(Skerka et al., 2007; Yu et al., 2007; Schmidt et al., 2008; Kelly et al., 2010). Several 
studies show that the SNP causes a diminished binding to CRP (Laine et al., 2007; 
Skerka et al., 2007; Yu et al., 2007; Okemefuna et al., 2010), a stronger affinity for DNA 
and necrotic cells (Sjoberg et al., 2007) and a higher propensity to dimerise (Fernando 
et al., 2007). But there are conflicting reports as to whether glycosaminoglycan binding 
is affected (Clark et al., 2006; Herbert et al., 2007; Yu et al., 2007). Before discussing 
the link between CFH and AMD, I will first introduce the affected cells and tissues of 
the retina. 
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1.3. Retina 
The eye can be functionally split into two halves (Figure 1.3A). The anterior half 
includes the cornea, iris, lens and ciliary body which together focus light onto the 
posterior half of the eye. Here the sensory retina processes light into electrical signals 
that are transmitted to the visual cortex via the optic nerve. The retina is a multi-
layered structure of predominantly neurons (neuroretina) and RPE. Bruch’s membrane 
separates the retina from the outer choroidal capillary network, the choriocapillaris. 
 
1.3.1. Neuroretina 
The neuroretina is a neural tissue containing neurons, glial cells and blood vessels. The 
neurons form three main cellular layers, the innermost photoreceptors, the bipolar, 
horizontal and amacrine cell layer, and the outermost ganglion cell layer. Toluidine 
blue staining of the neuroretina reveals 6 visually distinct layers (Figure 1.3B). The 
innermost layer contains the photoreceptor inner and outer segments (IS and OS) 
which synthesise and store the photosensitive pigments. Inward of the photoreceptors 
lies the outer nuclear layer (ONL) which contains the nuclei of the photoreceptors. The 
outer plexiform layer (OPL) contains synapses between the photoreceptors, bipolar 
and horizontal neurons. The inner nuclear layer (INL) lies in the middle of the retina 
and contains the nuclei of the bipolar, horizontal and amacrine neurons. Inward of the 
INL is the inner plexiform layer (IPL) which contains synapses between the bipolar, 
amacrine and ganglion cell layers. The innermost layer bordering the vitreous humour 
is the ganglion cell layer (GCL) which contains the cell bodies of the ganglion cells.  
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1.3.1.1. Photoreceptors 
There are two types of photoreceptors; rods and cones. In humans, the peripheral 
retina contains predominantly rods which are sensitive to low levels of light whereas 
cones are the dominating photoreceptor of central vision. Three types of cones, which 
are sensitive to either long (red), medium (green) or short (blue) wavelengths of light, 
allow colour vision. In nocturnal rodents the majority of photoreceptors are rods 
(Carter-Dawson and LaVail, 1979). Photoreceptors are made up of IS and OS connected 
by a cilium, with the nucleus located between the cilium and the synaptic terminal.  
The photosensitive pigment, opsin, is composed of a G-protein coupled receptor 
bound by a chromophore, 11-cis-retinal. The photosensitive opsins are synthesised in 
the IS and are transported to the OS, whereas the chromophore is regenerated 
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through delivery to the RPE as part of the visual cycle.  Rod OS contain rhodopsin 
which is packed into membranous discs distinct from the ciliary plasma membrane, 
whereas cone-opsins are stacked on invaginations of the ciliary plasma membrane.  
 
1.3.1.2. Glial cells 
The retina, as with other parts of the central nervous system, contains non-neuronal 
glial cells which support the function of both the neurons and blood vessels to 
maintain homeostasis. The retina contains three types of glial cells; Müller cells, 
astrocytes and microglia. Müller cells span the length of the retina between the two 
limiting membranes. Their apical villi form adherens junctions and desmosomes with 
each other and the IS of the photoreceptors to form the outer limiting membrane 
(OLM). Their wide endfeet along with the basement membrane form the inner limiting 
membrane (ILM), separating the vitreous from the retina. Müller cell processes form a 
close relationship with axons and blood vessels. They have a multitude of functions 
such as structural support, maintenance of ionic homeostasis, metabolic support and 
regulation of blood flow (Bringmann et al., 2006). Astrocytes also support the 
functions of neurons and blood vessels, but are restricted to the GCL. Microglia are 
tissue resident macrophages which aid phagocytosis of dying cells and debris. 
 
1.3.2. Retinal pigment epithelium 
The RPE is a cobblestone monolayer of polarised pigmented epithelium which under 
normal conditions is mitotically inactive. Located between the choroid and the 
neuroretina, the RPE is integral to homeostasis of the retina (Figure 1.3C). The apical 
surface of the RPE forms sheet-like microvilli which extend up into the 
interphotoreceptor matrix and engulf the OS of the photoreceptors upon daily 
circadian shedding.  The basal surface of the RPE forms convoluted infoldings which 
maximise the surface area for metabolic exchange with the choroidal vasculature. The 
RPE is polarised whereby the apical and basal halves differ in their structure, secretion 
of factors, expression of membrane bound proteins, organisation of organelles and 
junctional proteins. The six major functions of RPE have been comprehensively 
reviewed by Strauss (2005) and are summarised below. 
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1.3.2.1. Phagocytosis of shed outer segments 
Photoreceptor OS are continually turned over to prevent build-up of photo-oxidation 
by-products. Each day roughly 10% of the most distal OS is shed and phagocytosed by 
the RPE (Young and Bok, 1969). The shedding of OS is regulated by circadian rhythms 
where lights off initiates a wave of cone OS shedding and lights on initiates a burst of 
rod OS shedding. The three main steps of OS phagocytosis are binding, signalling 
events and subsequent internalisation. The αv 5 integrin, expressed on the apical 
surface of the RPE, must become activated for binding (Finnemann et al., 1997). 
Activation of αv 5 initiates a signalling cascade whereby activated focal adhesion 
kinase phosphorylates and activates the tyrosine kinase c-mer, which leads to 
downstream second messenger signalling. Tyrosine kinase signalling triggers an 
increase of intracellular inositol 1,4,5-triphosphate, Ca2+ mobilisation and  stimulates 
actin dynamics via modulators such as annexin 2 (Law et al., 2009) to drive OS 
internalisation. 
 
1.3.2.2. Preventing light induced oxidation 
The retina is exposed to almost constant light during conscious hours. A combination 
of light and a high oxygen and lipid content together favour oxidative reactions, 
leading to the potential generation of toxic free radicals. The RPE limits this process by 
the expression of antioxidants, pigment granules and repair mechanisms. Most 
importantly, the specialised organelles containing the pigment melanin, melanosomes, 
are polarised towards the apical surface of the cell for maximal absorption of scattered 
light. In rodents there is movement of melanosomes into the apical processes upon 
lights on. Although the reason for this movement is not known, it is speculated that it 
is related to the physical constraints of phagocytosis (Futter et al., 2004). This process 
has not been studied in humans or primates.  
 
1.3.2.3. Selective transport  
Tight junctions which seal neighbouring RPE cells together are important in 
maintaining the outer blood-retinal barrier (BRB). These tight junctions control the 
paracellular transport of water, ions, metabolites, proteins and cells between the 
choroid and the retina. Therefore the RPE must regulate the bi-directional transport of 
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these substances to meet the needs of the retina. The retina requires delivery of 
glucose, nutrients, retinal and lipids, and the removal of metabolites and metabolic 
water, and RPE cells are equipped with transporters for these substances on both 
apical and basal surfaces. 
 
1.3.2.4. Visual cycle 
11-cis-retinal is transformed by light energy to all-trans-retinal in the OS. Conversion of 
all-trans-retinal back to 11-cis-retinal takes place in the visual cycle which occurs in two 
steps. The first step is carried out in the photoreceptors where all-trans-retinal is 
transported to the cytosolic space where it reacts with phosphatidylethanolamine and 
retinol dehydrogenase to become all-trans-retinol. Since photoreceptors lack the 
enzymes required for re-isomerisation, all-trans-retinol is transported to the RPE via 
interstitial retinol binding proteins. In the RPE, cellular retinol binding proteins guide 
the all-trans-retinol to an enzyme complex which esterifies, re-isomerises and oxidises 
it into 11-cis-retinal. The delivery of 11-cis-retinal back to the photoreceptors 
completes the visual cycle (Thompson and Gal, 2003). 
 
1.3.2.5. Secretion by the RPE 
The RPE secretes a variety of proteins to maintain the structure and function of the 
retina, Bruch’s membrane and choroid. Some proteins are secreted in a polarised 
fashion in order to carry out specialised functions such as the neuroprotective and 
anti-angiogenic pigment epithelium-derived factor (PEDF) which is secreted apically 
(Becerra et al., 2004). The RPE secrete a variety of proteins and enzymes to maintain 
turnover of the extracellular matrix, growth factors and several immunological 
proteins including complement components, chemokines and interleukins. Secretion 
by RPE cells is regulated, in part, by intracellular free Ca2+ which is tightly regulated by 
the expression of transporters and ion channels (Rosenthal and Strauss, 2002).  
 
1.3.2.6. Buffering of ions in the subretinal space 
Effective electrical conductance in neurons is dependent on the buffering of ions by 
neighbouring non-neuronal cells. In the retina this is achieved by Müller glia cells and 
the RPE cells. The excitability of the photoreceptors is dependent on the 
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concentrations of ions in the subretinal space. RPE cells maintain ion homeostasis in 
this part of the retina by controlling the K+ conductance across their apical and basal 
membranes. In the dark, photoreceptors maintain a dark current which involves influx 
of Na+ and Ca2+ and efflux of K+. RPE cells buffer the subretinal K+ concentration by 
transporting K+ ions from the subretinal space towards the choroid. However, upon 
light stimulus K+ efflux from the photoreceptors declines and the K+ concentration in 
the subretinal space diminishes. The RPE counteracts this by switching from 
basolateral to apical efflux of K+. This process must be fast to keep up with neuronal 
transmission and RPE cells are therefore equipped with voltage-gated K+ channels 
(Wimmers et al., 2007). 
 
1.3.3. Bruch’s membrane 
Bruch’s membrane is an acellular pentalaminar structure which separates the choroid 
from the RPE. It provides structural support, acts as a scaffold for bio-active molecules, 
and forms part of the BRB to regulate movement of waste and nutrients between the 
RPE and the choroid. The five layers consist of a central lamina of elastic fibres 
sandwiched between two collagen layers, with two external basement membrane 
layers of the RPE and the choroid. Its composition and turnover is maintained by both 
the choroid and RPE (Booij et al., 2010). 
 
1.3.4. Blood supply 
The retina has two blood supplies (Figure 1.4). The outer retina is dependent on the 
blood supply of the choroid which has the highest perfusion rate in the body. The 
second blood supply, the retinal vessels, supports the retina between the ILM and 
OLM. Due to the multi-layered nature of the retina, the retinal vessels form three 
separate plexuses. The inner plexus contains the larger vessels and a capillary network. 
During development, vessels from the inner plexus dive down towards the outer edge 
of the INL and anastomose to form a deep capillary plexus. Finally, a third plexus called 
the intermediate capillary plexus forms between the inner and deep plexuses along 
the inner edge of the INL.  
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1.3.5. Blood-retinal barrier 
The BRB is essential for maintaining homeostasis within the retina. It is comparable to 
the blood-brain barrier which regulates transport of ions, proteins, fluid and cells to 
and from the brain.  The two blood supplies of the retina means that there is both an 
inner and outer BRB. The inner BRB refers to the retinal vessels where the vascular 
endothelial cells are connected by tight junctions restricting diffusion paracellularly. 
Müller cells, astrocytes and pericytes are also thought to contribute toward the barrier 
properties of the inner BRB. The outer BRB is maintained by Bruch’s membrane and 
tight junctions between RPE cells, because the endothelial cells of the choriocapillaris 
are heavily fenestrated and hence permeable. 
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1.3.6. Immune regulation in the retina 
The eye is considered an immune privileged site where several immunoregulatory 
mechanisms exist to protect vulnerable neural tissue by minimising bystander damage 
involved with inflammation. Such mechanisms include the BRB, immune deviation to 
self-antigens and secretion of immunosuppressive cytokines (Streilein, 2003). 
Breakdown of immune privilege can lead to autoimmune responses, infection and 
immune-mediated diseases such as uveitis and AMD. 
 
The RPE plays an important role in maintaining immune privilege of the subretinal 
space but also compensating for it by taking on several immune-related functions 
(Zamiri et al., 2007). The RPE expresses membrane bound receptors for immune 
recognition (toll-like receptors (TLR), Fc  receptors, complement receptors) and 
antigen presentation (major histocompatibility complexes I & II) (Detrick and Hooks, 
2010). RPE cells are able to respond to and secrete a variety of cytokines and 
chemokines. In a normal state the RPE secretes immunosuppressive cytokines such as 
transforming growth factor- , IL-10 and IFN  However, RPE cells also secrete several 
pro-inflammatory cytokines and chemokines for example in response to C5a (Fukuoka 
et al., 2003), CRP (Wang et al., 2010) or fibronectin (Austin et al., 2009) stimulation. 
Expression of membrane-bound and soluble cytokine receptors also allows the RPE to 
adapt its functions to the surrounding cytokine environment. For example, IL-1  
(Holtkamp et al., 1998), tumour necrosis factor-α (TNFα) (An et al., 2008), IFN  
(Nagineni et al., 2007) or a combination of IFN , TNFα and IL-1  (Li et al., 2007; Kutty 
et al., 2010; Nagineni et al., 2011) all induce changes in RPE secretion. 
 
1.3.7. Specialisations of the macula 
The macula is a specialised central region of the retina in humans and primates. In the 
centre of the macula there is a roughly 1 mm region called the fovea which has the 
highest visual acuity and is exclusively populated by cone photoreceptors. Although 
several structural and morphological differences have been found between the macula 
and the peripheral retina, the region still remains largely uncharacterised. Unique 
anatomical features of the macula include the foveal avascular zone (Gariano et al., 
2000) and a high density of photoreceptors which is responsible for this region having 
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the highest metabolic rate in the retina. The RPE cells underlying the macula have 
been shown to be more pigmented and smaller (Streeten, 1969), and the elastin layer 
of the Bruch’s membrane at this region is six fold thinner in order to aid fast diffusion 
(Chong et al., 2005). The macula has a yellow appearance which is due to the presence 
of macula pigments, lutein and zeaxanthin (Bone et al., 1985). The macula is a 
vulnerable area of the retina since several retinal diseases manifest in this region 
including macular telangiectasia, progressive cone dystrophy, rod-cone dystrophy, 
benign concentric macular dystrophy, Stargardt’s disease, Batten’s disease and AMD.  
 
1.4. Age-related macular degeneration 
AMD, as the name suggests, is a disease in which the macula of elderly people 
progressively degenerates. Originally described as guttate senile choroiditis by 
Nettleship in 1884, AMD is the leading cause of legal blindness in western countries, 
and causes 8.7% of blindness worldwide (Resnikoff et al., 2004). Although the macula 
is a comparatively small area of the whole retina, it accounts for the majority of central 
vision and therefore any degeneration in this area causes a significant impact on sight.  
  
There are two main subcategories of AMD, atrophic (formerly known as dry) and 
neovascular (formerly known as wet). Early stages of the disease are characterised by a 
change in retinal pigmentation and the presence of extracellular lipoproteinaceous 
deposits, termed drusen, basal to the RPE. Progression of the disease in the majority of 
patients is atrophic, characterised by detachment and death of the RPE and 
subsequent atrophy of overlaying photoreceptors. On average, 15% of patients will 
progress to neovascular AMD where the growth of choroidal vessels into the retina 
causes haemorrhage and scarring (Ferris, III et al., 1984). However, rare cases of AMD 
have also exhibited the neovascular form switching to the atrophic form or in other 
cases, both types progressing at once. 
 
1.4.1. Early clinical symptoms 
The earliest clinical signs of AMD are the formation of basal laminar and linear deposits 
(BlamD, BlinD). BlamD form between the RPE basal plasma membrane and the RPE 
basal lamina, and consist of membranous debris and collagen. BlinD form within the 
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inner collagenous layer of the Bruch’s membrane, and consist of vesicular material 
(Curcio and Millican, 1999).  
 
In addition to these deposits, drusen form between the basal lamina of the RPE and 
the inner collagenous layer of the Bruch’s membrane. Drusen are yellowish 
extracellular deposits visible by fundoscopic eye examination. The presence of drusen 
is a normal feature of ageing, however a change in number, size, colour, shape, 
distribution or solid appearance can be an indicator for early signs of AMD. Clinicians 
categorise these features of drusen to diagnose patients and predict progression of the 
disease (Pauleikhoff et al., 1990). Drusen are extracellular aggregates whose contents 
include lipids, carbohydrates, cellular materials and over 140 proteins.  A proteomic 
comparison of drusen from AMD sufferers and age-matched controls showed they 
shared 65% of the same proteins (Crabb et al., 2002). The composition of drusen is 
similar to that of extracellular deposits seen in other diseases such as atherosclerosis 
and amyloidosis, suggesting common processes in their pathogenesis (Mullins et al., 
2000).  
 
The origins of drusen are not fully characterised, although they are thought to be a 
combination of RPE debris, including phagocytosed material from the photoreceptors, 
extruded basally (Anderson et al., 2001; Malek et al., 2003), and plasma proteins from 
the choroid diffusing across Bruch’s membrane. The driving force for their formation is 
also not fully understood, although a commonly held view is that complement 
activation and inflammation are key processes in drusen biogenesis. This is supported 
by the significant presence of complement and inflammatory proteins found in drusen 
(Mullins et al., 2000; Hageman et al., 2001; Johnson et al., 2001).  
 
Enhanced lipofuscin in the RPE is another early sign of AMD (Marmorstein et al., 2002). 
Lipofuscin is an autofluorescent mix of coloured lipid-soluble pigments. Like drusen, 
the presence of lipofuscin is also a normal feature of ageing (Wing et al., 1978) and its 
biogenesis is not fully understood. Disruption to the visual cycle can lead to a build-up 
of toxic bis-retinoids such as N-retinylidene-N-retinyl-ethanolamine (A2E) and photo-
oxidation of these molecules contributes to lipofuscin generation. Lipofuscin is not 
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easily digested or catabolised by RPE cells, and as it accumulates it becomes vulnerable 
to peroxidation generating damaging reactive oxygen species. Like drusen, it is not 
clear whether lipofuscin formation is a primary cause of AMD, a risk factor or an early 
secondary effect.  
 
1.4.2. Late stage disease 
Progression of atrophic AMD is characterised by the loss of RPE cells which leads to 
degeneration of the overlying photoreceptors. Cell death can extend into the outer 
retinal layers resulting in dramatic thinning of the retina in the macula. As 
compensation for the loss of RPE, surrounding RPE proliferate and become 
hyperpigmented. 
 
Neovascular AMD is the main cause of sudden irreversible vision loss. Blood vessels 
from the choroid penetrate Bruch’s membrane and can advance into the 
photoreceptor layers where they may anastomose with retinal blood vessels. These 
blood vessels are often leaky causing haemorrhage and detachment of the RPE. 
Formation of disciform scars in the RPE and neural layers of the macula causes 
permanent irreversible damage and is the main cause of vision loss in AMD. Several 
constituents of drusen, C3a, C5a (Rohrer et al., 2009), carboxyethyl pyrrole (CEP) 
adducts (Ebrahem et al., 2006) and bis-retinoids (Iriyama et al., 2009), have been 
shown to stimulate neovascularisation of the choroid.  
 
1.4.3. Pathogenesis 
AMD is a multifactorial disease whose pathogenesis is determined by many genetic 
and environmental factors, which makes this disease interesting to study but difficult 
to resolve. The use of large population based studies have helped to characterise 
prevalence of the disease in different populations and investigate candidate risk 
factors. The major studies have been undertaken in America (The Beaver Dam eye 
study) (Klein et al., 1992), The Netherlands (The Rotterdam study) (Vingerling et al., 
1995)) and Australia (The Blue Mountain eye study) (Mitchell et al., 1995). All studies 
show an age-specific frequency for AMD amongst the population.  
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1.4.3.1. Environmental risks to AMD 
Several environmental factors have been shown to be associated with AMD. These 
include sunlight exposure (Taylor et al., 1990), alcohol consumption (Chong et al., 
2008), hyerptension and cardiovascular disease (Hogg et al., 2008), smoking (Klein et 
al., 2008), and body mass index (Seddon et al., 2003). Of these, smoking has had the 
most consistent results, and is now well established as a risk factor for AMD. Smoking 
can link into two main theories of AMD, inflammation and oxidative stress. Smoking 
impairs the generation of antioxidants, possibly by stimulating inflammation. Smoking 
has also been shown to decrease plasma levels of CFH (Esparza-Gordillo et al., 2004), 
luteal pigment in the retina (Hammond, Jr. et al., 1996), reduce choroidal blood flow 
(Bettman et al., 1958), reduce drug detoxification by the RPE, activate the immune 
system, and potentiate nicotine angiogenic activities (Pryor et al., 1983; Beatty et al., 
2000; Suner et al., 2004). In contrast, eating fish and omega-3 fatty acids were found 
to be protective against AMD (Seddon et al., 2006). 
 
1.4.3.2. Genetic predisposition to AMD 
Since the 1960s, clinicians have reported the high frequency of family members of an 
AMD patient who also develop the disease (Braley, 1966) pointing to the role of 
genetics in the aetiology of AMD. Familial aggregation studies such as the Rotterdam 
study showed that a quarter of late stage AMD cases were genetically determined 
(Klaver et al., 1998). A large scale study on monozygotic and dizygotic twins showed 
that genetics determined 46% of overall disease susceptibility, which increased to 67% 
for intermediate and 71% for late-stage disease. Therefore the likelihood of 
progressing to late stage disease is more dependent on genetic rather than 
environmental influence (Seddon et al., 2005a). 
 
The first gene found to be associated with AMD was adenosine triphosphate-binding 
cassette, subfamily A, member 4 (ABCA4). This gene was chosen as a candidate gene 
for a gene association study because of its association with a juvenile form of AMD, 
Stargardt disease. Here they observed that mutations in the ABCA4 gene associated 
with 4% of AMD patients tested. Although the same group went on to replicate their 
results in a larger cohort, indeed showing a larger effect of the gene (Allikmets, 2000), 
  
 
47 
 
no other groups have been able to replicate their findings. Many studies since 1997 
have identified the association of other candidate genes with AMD (Haddad et al., 
2006; Katta et al., 2009), and genome wide linkage studies have identified regions of 
the genome which segregate with known AMD susceptibility markers at a higher 
frequency in cases than in controls (Deangelis et al., 2011). Two chromosomal regions 
with the most consistent logarithm of odds score are 1q23.3-31.1 and 10q26. 
 
A new era of studying complex genetic diseases began when the first (as regarded by 
the National Human Genome Research Institute) genome wide association study, was 
published in 2005. This study examined over 100,000 SNPs throughout the human 
genome with the aim of identifying common risk alleles for AMD (Klein et al., 2005). 
Using 96 cases and 50 controls, this study identified a SNP in CFH to have a large effect 
size, where being heterozygous increased risk 4.6 fold and homozygous 7.4 fold. CFH is 
located on chromosome 1q within a region highly associated with AMD susceptibility. 
This SNP, rs1061170, replaces a thymine with a cytosine at position 1277 in exon 9 
which leads to a histidine (H) to tyrosine (Y) mutation at position 402 (Y402H), in SCR 7 
of the protein.  The association of the Y402H mutation with AMD was a landmark 
discovery with three other separate studies reported in the same year corroborating 
the finding (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005). 
 
Other SNPs in CFH have also been shown to associate with AMD, several of which have 
been suggested to have a larger effect than Y402H. A further study showed four 
common haplotypes surrounding CFH, two of which offer protection and two which 
confer risk to AMD (Li et al., 2006). 
 
After CFH, age-related maculopathy susceptibility protein 2 (ARMS2) is the gene with 
the second largest odds ratio (Rivera et al., 2005), and like CFH it lies within a region 
highly associated to AMD susceptibility, 10q26. The cellular function of ARMS2 is still 
unknown, and the localisation of the protein is disputed between the mitochondria 
(Kanda et al., 2007) and cytosol (Wang et al., 2009b), and other studies have reported 
ARMS2 to be secreted component of the extracellular matrix (Kortvely et al., 2010). 
Results from genome-wide scans also implicated a gene next to ARMS2 on 10q26, 
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high-temperature requirement A 1, (HTRA1). HTRA1 is a serine protease which in the 
retina has been shown to act on fibromodulin, clusterin, disintegrin, metalloproteinase 
domain-containing protein 9 and vitronectin (An et al., 2010) and its overexpression in 
mice showed altered elastogenesis of Bruch’s membrane (Vierkotten et al., 2011). 
Several SNPs in this gene have now been shown to associate with AMD risk but a SNP 
in the promoter region has been the most consistent. This SNP has been shown to 
enhance mRNA expression in RPE (An et al., 2010).  
 
To date, over 50 genes have been implicated in the pathogenesis of AMD, confirming 
its complex-genetic disease definition. The majority of these have only been identified 
in one or two studies, with a similar number of studies unable to confirm the original 
findings (Lotery and Trump, 2007; Katta et al., 2009), and the majority conveying only 
small effects.  Since clinical symptoms and progression vary vastly between AMD 
patients, therefore it may be that different haplotypes are responsible for different 
categories of the disease. However, allelic variations in four of the genes, CFH, ARMS2, 
C2 and CFB account for more than half of the genetic risk (Maller et al., 2006), 
highlighting the significance of the complement system to AMD.  
 
1.4.4. Disease mechanisms in AMD 
By definition, age has the largest influence on AMD susceptibility. In the United States 
of America, prevalence in the 5th decade of life is 2.1% however this increases to over 
35% in the 9th decade (Friedman et al., 2004). Ageing of the retina is associated with 
several well-characterised structural and functional changes which are thought to 
predispose the retina to AMD. The additive effect of environmental and genetic risk 
factors to ageing tips the balance from homeostasis to pathology. There are four main 
mechanisms which become dysregulated with normal ageing, and the following 
sections describe how normal ageing affects these cellular functions and how they 
predispose the retina to AMD. 
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1.4.4.1. Oxidative stress 
The retina is one of the most vulnerable tissues to oxidative damage in the body. It has 
the highest consumption of oxygen, an almost constant exposure to light and contains 
an unusually high lipid content rich in unsaturated fatty-acids. Oxidation of lipids 
generates highly reactive molecules that can cause free-radical chain reactions, and 
lipid peroxidation products which modify proteins.  These lipid peroxidation products 
have been shown to affect lysosomal degradation, and influence exocytosis of un-
degraded proteins from the basal side of the RPE (Krohne et al., 2010). This material 
extruded basally from the RPE contributes towards the formation of drusen. Although 
the retina is well equipped with antioxidant enzymes (Cai et al., 2000) normal ageing in 
the RPE is associated with a decrease in these enzymes and also melanin (Bonilha, 
2008). Melanin content reduces with age because there is an increased tendency for 
melanosomes to fuse with both lysosomes (melanolysosomes) and lipofuscin 
(melanolipofuscin), diminishing the anti-oxidative capacity of melanin (Sarna et al., 
2003). Additionally, lipofuscin which is known to increase with age, is particularly toxic 
when oxidised (Wassell et al., 1999).  
 
The study of ageing has largely focused on the accumulative effects of oxidative stress 
on macromolecules and the accumulation of nuclear and mitochondrial mutations 
(Van et al., 2003; Kregel and Zhang, 2007; Romano et al., 2010).   The consequences of 
oxidative stress cause dysregulation of numerous RPE functions (Cai et al., 2000; 
Jarrett et al., 2008), including the ability of RPE cells to regulate complement 
deposition on the cell surface (Thurman et al., 2009).  
 
There are several reports which directly or indirectly highlight the role of oxidative 
stress in AMD. For example, AMD patients who supplement their diet with anti-
oxidants slow the progression of disease (Age-related Eye Disease Study, 2001), and 
proteomic analysis showed that drusen from AMD patients contain more oxidised 
lipids and protein adducts resulting from oxidative damage than those from age-
matched controls (Crabb et al., 2002). The most common adduction of proteins found 
in AMD eyes is CEP, which is an oxidative fragment of docosahexaenoic acid (the most 
abundant long chain polyunsaturated fatty acid in the retina) (Gu et al., 2003). Indeed, 
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mice injected with albumin conjugated with CEP develop AMD-like symptoms 
(Hollyfield et al., 2008; Hollyfield et al., 2010). Furthermore, mice lacking anti-oxidants 
develop a geographic atrophy-like phenotype (Imamura et al., 2006). 
 
Both environmental and genetic risk factors, which either increase oxidative stress or 
decrease the capacity of the retina to cope with oxidative stress, increase AMD 
susceptibility. Smoking, the most consistent environmental risk factor for AMD is 
known to reduce antioxidant levels, and cause mitochondrial DNA damage (Wang et 
al., 2009a), and several SNPs in anti-oxidant enzymes increase the risk of AMD. 
 
1.4.4.2. Lipid metabolism 
Photoreceptors contain an unusually high lipid content, making up 15% of the total 
wet weight compared to 1% in other cells (Wright et al., 2010). The phagocytosis of 
shed photoreceptor OS therefore involves coping with a significant level of lipid 
metabolism. Internalised OS are contained within phagosomes which fuse with 
lysosomes for degradation and recycling (Kevany and Palczewski, 2010). Normal ageing 
has been shown to decrease lysosomal efficiency which leads to an accumulation of 
un-degradable lipid that in turn enhances the risk of lipid peroxidation (discussed 
above) and the formation of lipofuscin within the RPE (Wing et al., 1978; Rajawat et 
al., 2009). Lipofuscin causes dysfunction of several RPE cell activities including 
interference with melanin (Wang et al., 2006), clogging of the cytoplasm (Yasukawa et 
al., 2007), inhibition of mitochondrial function (Vives-Bauza et al., 2008) and is 
vulnerable to photo-oxidation (Schutt et al., 2000). 
 
Several genetic risk factors have linked dysregulation of lipid metabolism with AMD 
susceptibility. Mutations in genes involved in lipid metabolism associated with AMD 
susceptibility are summarised in Table 1.2. 
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1.4.4.3. Immune regulation  
Dysregulation of the immune system is accepted to be a key feature in AMD 
progression. Normal ageing of the retina is associated with immunological activation 
which can induce a low-grade inflammation named para-inflammation (Chen et al., 
2008; Xu et al., 2009; Chen et al., 2010). Features of para-inflammation include the 
activation of complement, activation of microglia in the neuroretina and accumulation 
of microglia in the outer retina. In AMD, immunological activation of the retina is 
uncontrolled and several features of the disease suggest that immune dysregulation 
may be a primary cause for disease onset. Initially the composition of drusen was the 
main point of evidence. However systemic characterisation of AMD patients has shown 
that CRP, IL-6, factor D and complement activation products are all elevated (Seddon 
et al., 2005b; Scholl et al., 2008), and patients with choroidal neovascularisation 
showed higher proportions of activated circulating monocytes (Cousins et al., 2004). 
Both CRP and amyloid P, known activators of the classical complement pathway, are 
also elevated in the choroid of AMD patients (Seddon et al., 2004; Johnson et al., 
2006). A mouse model for AMD corroborated the role of the immune system in the 
pathogenesis of AMD where monocyte chemotactic protein-1 (MCP1) and MCP1 
receptor null mice develop an AMD-like phenotype (Ambati et al., 2003). 
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SNPs in proteins involved in the immune system (Table 1.3), and in particular the 
complement system (Table 1.4), confirm the role of the immune system in AMD 
susceptibility. 
 
 
 
 
 
1.4.4.4. Bruch’s membrane structure and turnover 
Normal ageing of Bruch’s membrane causes it to become thicker, stiffer, have an 
altered chemical composition and accumulate cell debris (Okubo et al., 1999; Ugarte et 
al., 2006). With normal ageing, Bruch’s membrane alterations compromise diffusion of 
nutrients from the choroid to the retina. Patients with AMD are less able to cope with 
the normal effects of ageing in the retina since the combination of inflammation, 
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oxidative stress and altered lipid metabolism further compromises Bruch’s membrane. 
Bruch’s membrane in AMD eyes contains modifications such as an increase in lipid 
content and proteins modified by advanced glycation end-products (AGE). These AGE 
modifications have been shown to enhance protein cross-linking, be detrimental to 
cellular function, and are hypothesised to contribute towards the formation of drusen 
(Baynes, 2001; Glenn et al., 2009). 
 
Bruch’s membrane composition in AMD patients has also been shown to lose its ability 
to bind CFH (Kelly et al., 2010). Bruch’s membrane heavily relies upon CFH since it does 
not express surface bound complement regulators. Loss of the ability to bind CFH 
makes this site more vulnerable to uncontrolled complement activation. Decreased 
binding may be due to a SNP in CFH or composition of Bruch’s membrane. Expression 
of tissue inhibitor of matrix metalloproteinase 3 (TIMP3) expression is enhanced in the 
Bruch’s membrane of AMD patients (Kamei and Hollyfield, 1999). TIMP3, known to be 
associated with a juvenile form of macular degeneration, also contains a SNP 
associated with AMD, highlighting its role in the disease. SNPs in proteins of the 
extracellular matrix or enzymes involved in their turnover that are found to be 
associated with AMD susceptibility are summarised in Table 1.5. 
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1.4.4.5. RPE dysfunction 
One of the main effects of ageing is the dysfunction of the RPE. Without a fully 
functioning RPE, the neuroretina cannot be supported, causing it to thin with age. 
Drusen are an early sign of RPE dysfunction. Environmental and genetic factors 
predispose people to AMD because they hinder the ability of the retina to cope with 
the normal ageing process.  Because the RPE serves many homeostatic functions, 
death or dysfunction of these cells has a dramatic effect on phenotype, and could at 
least partly explain why AMD is so variable amongst sufferers. 
 
1.4.5. AMD therapies 
Only in the past two decades have therapies for AMD become available for patients, 
however these are limited to the neovascular form of AMD. Although neovascular 
AMD represents only 15% of AMD patients, it accounts for the majority of visual loss 
associated with this disease.  
 
Thermal laser therapy, one of the first treatments for neovascular AMD, uses lasers to 
photocoagulate the CNV membranes disrupting new vessel growth. The disadvantage 
of this therapy was that it also caused destruction of overlying healthy tissue (Kallitsis 
et al., 2007). This treatment was improved when Novartis developed Visudyne®, a 
photosensitiser which can be injected intravenously and is subsequently activated by a 
laser in the region of the neovascularisation. This photodynamic therapy (PDT) 
generates the release of damaging free radicals in a localised area and destroys the 
CNV membranes without damaging the overlying retina. 
 
Currently, new biological reagents have been developed for the treatment of 
neovascular AMD which achieve better outcomes than PDT (Ciulla and Rosenfeld, 
2009). These therapies target vascular endothelial growth factor (VEGF) which is a 
potent inducer of CNV. The first anti-VEGF treatment was pegaptanib sodium 
(Macugen®, Pfizer) which is a pegylated aptamer that targets only the VEGFA165 
isoform. This has been superseded by the generation of a monoclonal antibody 
fragment, ranibizumab (Lucentis®, Novartis) which recognises all VEGFA isoforms. 
Although patient outcomes have been very effective in a proportion of patients 
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treated (Horster et al., 2011), it does not work for everyone and the treatment is 
expensive. In some instances to save costs, AMD patients are treated with a cheaper 
alternative, bevacizumab (Avastin®, Roche) which is a full-length humanised 
monoclonal antibody to VEGFA. In fact, bevacizumab was the predecessor to 
ranibizumab and both were developed by Genentech. Bevacizumab is licensed for 
treatment of colorectal carcinoma, although it has been prescribed ‘off-label’ to AMD 
patients. Another anti-VEGF treatment currently under clinical trials, is VEGF Trap-Eye 
which has a higher affinity for VEGF than monoclonal antibodies (Heier et al., 2011).  
VEGF Trap-Eye consists of the extracellular portions of VEGF receptors 1 and 2 fused to 
the fragment crystallisable region of human IgG. 
 
The expense of new biological treatments may be mitigated by the development of 
pharmacogenetics which could, in the future, impact how AMD patients are treated. 
With increasing knowledge of genetic risk alleles, more studies are being carried out to 
assess the success of AMD treatments in relation to individual genotype (Nischler et 
al., 2011; Wickremasinghe et al., 2011). In the future it may be possible to genotype 
patients prior to choosing personalised treatment options. 
 
Patients with atrophic AMD have considerably fewer treatment options available to 
them. At present, treatment strategies involve dietary supplementation with anti-
oxidants and zinc (Olson et al., 2011), a recommendation to stop smoking and regular 
check-ups to monitor progression to the neovascular form. Since 85% of patients have 
atrophic AMD, there is a substantial unmet clinical need for licensed treatments. With 
fast progress in unravelling AMD pathogenesis, many targets for potential atrophic 
AMD treatments have been identified and are under current clinical trial (reviewed by 
Yehoshua et al., 2011)  such as anti-inflammatories, anti-oxidants, complement 
inhibitors, immunosuppressant agents, TLR inhibitors, stem cell therapies (Du et al., 
2011) and PEDF gene therapy (Rasmussen et al., 2001). 
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1.5. Thesis aims 
The molecular mechanisms by which SNPs in CFH are associated with AMD 
susceptibility have not been clearly defined. In part, this is due to a lack of 
understanding of the role of CFH within the retina.  A report which characterised aged 
Cfh-/- mice demonstrated an important requirement for CFH in maintaining a healthy 
retina (Coffey et al., 2007). Through studying the secretion of CFH from RPE cells and 
further characterisation of the Cfh-/- mouse, this thesis aims to investigate the role of 
CFH in the retina, in order to clarify its significance in AMD pathogenesis.  
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Chapter 2: Materials and Methods 
All reagents were purchased from Sigma Aldrich unless specified otherwise. Catalogue 
numbers are indicated in brackets after company name. 
 
2.1. In vitro techniques 
2.1.1. Cell culture 
ARPE19, a spontaneously arising immortalised human RPE cell line, was used between 
passages 20-30. ARPE19 and primary porcine RPE were maintained in either high 
glucose Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, 41965-039) 
containing 292 g/ml L-glutamine or X-VIVO™ 15 (Lonza, BE04-418F). Media were 
supplemented with 100 IU/ml penicillin and 100 g/ml streptomycin (PAA Laboratories 
Ltd, P11-010). DMEM was additionally supplemented with 10% or 1% heat-inactivated 
foetal calf serum (FCS-Invitrogen, 10108-165). ARPE19 cells were passaged with 0.05% 
trypsin - 0.53 mM ethylenediaminetetraacetic acid (EDTA) (Invitrogen, 15400-054) in 
Dulbecco’s phosphate buffered saline (PBS-Invitrogen, 14200067). Cells were grown in 
a 37°C humidified incubator with 5% CO2. 
 
2.1.2. Primary porcine RPE isolation 
Sow’s eyes were obtained from Cheale Meats Ltd and delivered on ice on the morning 
of slaughter. Once external tissue was removed, eyes were soaked in a 2.5% povidone-
iodine solution (Videne-Williams Medical Supplies, D748980) for 10 min and washed in 
an antibiotic solution containing 1000 IU/ml penicillin and 1 mg/ml streptomycin for 5 
min. In a sterile hood, the anterior halves were dissected with a scalpel and discarded 
along with the lens and vitreous humour. The posterior eyecups were filled with PBS. 
The neuroretinas were carefully peeled away from the underlying RPE, disconnected at 
the optic nerve head and discarded along with the PBS. 2 ml of 10X trypsin in PBS 
(0.5% Trypsin - 5.3 mM EDTA, Invitrogen, 15400-054) was added to eyecups and 
incubated for 30 min at 37°C. Trypsinised RPE were harvested by gentle agitation and 
washed in DMEM containing 10% FCS for 5 min at 800 revolutions per minute (rpm) at 
room temperature (RT) using an Eppendorf 5810 R centrifuge. RPE cells were pooled 
and plated at approximately one eye/9.6cm2. 
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2.1.3. Secretion assay 
RPE cells were grown to confluency in a 6-well plate (Nunc) prior to use in secretion 
assays. Cells were washed twice in PBS to remove traces of FCS from the culture 
medium. 1.2 ml of serum-free DMEM or X-VIVO™ 15 containing 100 IU/ml penicillin 
and 100 g/ml streptomycin was added per well. For the zero time point, media was 
added and immediately removed from one well. Plates were then placed into an 
incubator wrapped in wet tissue paper to prevent evaporation. In each 6-well plate 
four of the remaining wells were treated in an ‘accumulative’ fashion whereby spent 
media were collected from one well at 2 h, the second at 4 h, the third at 6 h and the 
last at 8 h (or in an extended time course 8, 24, 48 and 72 h). One well was treated in a 
‘serial’ fashion whereby spent media was collected and replaced with fresh serum-free 
media each time the accumulative samples were collected. After collection of spent 
media at various time points, cells were washed with PBS and lysed in boiling 2X 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer 
(0.125 M Tris-HCl-pH 6.8, 25% glycerol, 5.4% dithiothreitol, 2% SDS, 0.02% 
bromophenol blue). Prior to precipitation, cell debris in spent media was pelleted for 3 
min at 13,000 rpm in a table top centrifuge at RT. The supernatant was transferred 
into a fresh Eppendorf tube and where described, 100 l of 10 g/ml goat IgG 
(dissolved in DMEM) was added per sample. 
 
2.1.3.1. Cytokine stimulation 
For cytokine stimulation, IL-1 , IFN  and TNFα (R&D Systems, 201-LB, 285-IF, 210-TA) 
were diluted in 1.2 ml DMEM containing 100 IU/ml penicillin and 100 g/ml 
streptomycin. A range of concentrations (0-200 ng/ml) was tested and spent media 
collected after 8 h. Further experiments applied 100 ng/ml IFN , with spent media 
collected in both an accumulative and serial fashion over 8 h. 
 
2.1.3.2. Cycloheximide treatment 
Cycloheximide was dissolved in dimethyl sulphoxide (DMSO) and diluted to 10 M in 
DMEM containing 100 IU/ml penicillin and 100 g/ml streptomycin. 1.2 ml of DMEM 
containing or DMSO (vehicle control) was applied to ARPE19 cells in an 8 h secretion 
assay as described in Section 2.1.3. 
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2.2. Protein isolation and analysis techniques 
2.2.1. Trichloroacetic acid precipitation 
One volume of trichloroacetic acid (TCA) was added to four volumes of spent media, 
mixed, and incubated for a minimum of 30 min at 4°C. Precipitated proteins were 
pelleted in a table top centrifuge at 13,000 rpm for 10 min at 4°C. The supernatant was 
discarded and the pellet washed twice in 200 l ice-cold acetone. The pellet was dried 
at 95°C for 10 min and re-solubilised in 20 l 2X SDS-PAGE sample buffer (described in 
Section 2.1.3). 
 
2.2.2. Acetone precipitation 
One volume of ice cold acetone was added to 1.4 volumes of spent media, mixed, and 
incubated for 5 min at RT. Precipitated proteins were pelleted in a table top centrifuge 
at 13,000 rpm for 3 min at RT. The pellet was dried at 95°C for 10 min and re-
solubilised in 20 l 2X SDS-PAGE sample buffer (described in Section 2.1.3). 
 
2.2.3. Ammonium sulphate cut 
Saturated ammonium sulphate was added to spent media to give a final concentration 
of either 5% or 29%. Samples were mixed and rotated for 45 min at RT. Precipitated 
proteins were pelleted in a table top centrifuge at 13,000 rpm for 15 min at RT. 
Supernatants were transferred to a fresh tube and the pellet re-solubilised in 20 l 2X 
SDS-PAGE sample buffer (described in Section 2.1.3). Further volumes of saturated 
ammonium sulphate were added to recovered supernatant to increase the final 
concentration of ammonium sulphate, and the following steps repeated (from 5% to 
14, 25, 32, 41 and 50% ammonium sulphate, or from 29% to 55, 62, 67 and 71% 
ammonium sulphate).  
 
2.2.4. Heparin-agarose pull-down 
Heparin-agarose type I was washed twice in PBS, and pelleted in a table top centrifuge 
at 13,000 rpm for 1 min at RT. One volume of heparin-agarose was added to two 
volumes of spent media and rotated for 3.5 h at RT. The heparin-agarose was again 
pelleted and the supernatant precipitated with TCA (as described in Section 2.2.1). 
Heparin-agarose was washed six times in PBS. Finally, 150 l of 2X SDS-PAGE sample 
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buffer (described in Section 2.1.3) was added to the pellets and incubated for 5 min at 
95°C to solubilise proteins. Tubes were centrifuged and samples were analysed by SDS-
PAGE and western blotting.  
 
2.2.5. Polyacrylamide gel electrophoresis 
Resolving gels for SDS-PAGE were 0.375 M Tris-HCl (pH 8.8) and 8% acrylamide/Bis-
acrylamide for CFH analysis, and 10% in all other analyses. Stacking gels were 0.125 M 
Tris-HCl (pH 6.8) and 4% acrylamide/Bis-acrylamide. Gels contained 0.1% SDS and were 
polymerised with 0.05% ammonium persulphate and 0.1% 
tetramethylethylenediamine. Samples from Sections 2.2.1-4 were denatured for 5 min 
at 95°C prior to loading alongside a suitable molecular weight ladder (Bio-Rad, 161-
0374). Gels were run in electrophoresis grade SDS-running buffer (0.025 M Tris, 0.192 
M glycine, 0.1% SDS, National Diagnostics, EC-870) at 80 mV until proteins were 
stacked along the resolving/stacking interface upon which the voltage was increased to 
150 mV. 
 
Proteins were transferred from gels onto PVDF membrane (GE Healthcare, RPN303F) 
via wet transfer. For this, the membrane was activated in methanol for 5 min at RT and 
rinsed in transfer buffer (10% methanol, 0.025 M Tris, 0.192 M glycine, National 
Diagnostics, EC-880). The gel and membrane were sandwiched between filter papers 
and sponges soaked in transfer buffer. Transfer sandwiches were immersed in a tank 
of transfer buffer and run at 400 mA for 30 min per gel on ice. 
 
2.2.6. Western blotting 
All incubation steps were carried out on an orbital shaker. Membranes were blocked in 
blocking buffer (PBS-7% skimmed milk) for 1 h at RT. Primary antibodies were diluted 
(according to Table 2.1) in blocking buffer and applied to membranes overnight at 4°C. 
Membranes were washed six times for 5 min in washing buffer (PBS - 0.05% Tween). 
Horseradish peroxidise conjugated secondary antibodies were diluted in PBS - 3.5% 
milk, 0.025% Tween (according to Table 2.1) and applied to membranes for 1 h at RT. 
Membranes were again washed six times for 5 min in washing buffer. Membranes 
were developed using an enhanced chemiluminescence detection system (GE 
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Healthcare, RPN2109), for 3 min at RT and immediately developed using a Konica 
Minolta SRX-101A X-ray developer and X-ray film (Fuji photofilm, MRX 1824). 
 
 
 
2.3. In Vivo techniques 
2.3.1. Animals 
Cfh-/- mice were a generous gift from Prof. Matthew Pickering (Imperial College). Mice 
were generated through disruption of Cfh exon 3 using a gene targeting vector in 
embryonic stem cells. Cfh-/- mice have a 129/Sv x C57Bl/6 hybrid background (Pickering 
et al., 2002). Ex-breeding C57Bl/6 control mice of 6-9 months were purchased from 
Harlan Laboratories. Young C57Bl/6 mice were bred in house. Mice were housed in the 
Biological Resources Unit at the Institute of Ophthalmology; a UK Home Office 
approved animal facility. Cfh-/- breeding pairs were housed in isolated ventilated cages 
and all breeding pairs were fed a diet of Teklad global 19% protein extruded rodent 
diet (Harlan Laboratories, 2019). All other mice were housed on the open shelf and fed 
a diet of Teklad global 18% protein extruded rodent diet (Harlan Laboratories, 2018). 
All mice were exposed to 12 h light and 12 h dark cycles. 
 
Mice used for RNA isolation underwent cervical dislocation.  Perfused mice were first 
anaesthetised prior to perfusion with fixative. All other mice were killed with a rising 
CO2 concentration with subsequent cervical dislocation. After death, mice were 
immediately enucleated using curved forceps. 
 
Mice were used at either 7-8 weeks or 1 year ± 11 days for all analyses except for 
microarray analysis where mice were 7-8 weeks and 1 year 140 days ± 6 days. Mice 
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were killed at various times throughout the day except for ultrastructural analysis (see 
Section 2.4). 
 
2.3.2. Electroretinograms and visual evoked potentials 
Electroretinogram (ERG) and visual evoked potential (VEP) recordings were performed 
on 1 year 14 day ± 11 days mice in conjunction with Dr. E. Rebecca Longbottom of the 
cell biology department at The Institute of Ophthalmology. 
 
2.3.2.1. Animal preparation 
Mice were dark-adapted overnight and prepared for recordings under dim red 
illumination. Mice were anaesthetised by intraperitoneal injection with ketamix, 2 l/g 
body weight (37.5% ketamine, 25% Dormitor, Fort Dodge Animal Health Ltd) and 10 l 
atropine sulphate (600 g/ml, Hameln Pharmaceuticals) to aid breathing. The right eye 
was patched over to exclude light, and to the left eye, 2.5% phenylephrine 
hydrochloride and 1% tropicamide eye drops (Minims-Bausch & Lomb) were 
administered for dilation of the pupil and a local anaesthetic, 0.5% proxymetacaine 
hydrochloride (Minims-Bausch & Lomb) was applied. Each mouse was placed in the 
recording chamber on an electrically heated pad (CWE Inc., TC-100) to maintain a 37°C 
body temperature and secured to a bite bar before placing platinum electrodes. All 
needle electrodes were inserted subcutaneously using a 21 gauge (G) needle 
moistened with Kreb’s solution (NaCl 124 mM, KCL 2 mM, KH2PO4 1.25 mM, MgSO4 1 
mM, CaCl2 2 mM, NaHCO3 26 mM, glucose 10 mM). The VEP recording needle 
electrode was positioned at the skull in the region of the contralateral visual cortex 
and the VEP reference needle electrode was positioned at the nose. The ERG reference 
needle electrode was placed at the temple near the left eye and the ERG recording 
loop electrode was placed on the left cornea. The earth needle electrode was placed at 
the back near the tail of the mouse. The light-emitting diode stimulator was positioned 
over the left eye and the recording chamber sealed. 
 
2.3.2.2. Scotopic and photopic recordings 
Stimuli for the scotopic recordings were brief full field flashes of white light from 
darkness at varying intensity (-5.5 to 1 log cd/s/m2) by altering both the duration (3 s-
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1 ms) and attenuation (1000-1) of the stimulus. The frequency of the flashes was 0.67 
Hz at lower intensities, which was decreased to 0.33 and 0.17 Hz at the intermediate 
and higher intensities. 
 
For photopic recordings, mice were light adapted in the recording chamber for 20 min 
with a rod adapting background light (20 cd). Background light was maintained 
throughout photopic recordings where brief full field flashes of white light were 
applied at varying intensity (-1.4 to 1 log cd/s/m2) by altering both the duration (1-3 
ms) and attenuation (1000-1) of the stimulus. The frequency of flashes was 0.5 Hz. 
 
2.3.2.3. Data collection and analysis 
Electrode recordings from ERG and VEP electrodes were collected at the same time 
and were sent to an analogue to digital interface. Digital data were sent to the 
computer and interpreted by Observer software (Breakpoint Pty Ltd). After recordings, 
mice were sacrificed by cervical dislocation.  
 
ERG and VEP recordings were analysed using Reviewer software (Breakpoint Pty Ltd). 
For ERG data, amplitude and time to peak of the a-wave were measured from the 
baseline to the trough. The amplitude of the b-wave was measured from the trough of 
the a-wave to the peak of the b-wave. Time to peak of the b-wave was measured from 
baseline to the peak of the b-wave. VEP amplitude were measured from the peak of 
the positive wave to the trough of the negative wave, and time to peak was measured 
from baseline to the trough of the negative peak. 
 
2.4. Electron Microscopy 
2.4.1. Fixation  
For ultrastructural analysis all samples were prepared in the afternoon. For analysis of 
the RPE, enucleated eyes were immersed in Karnovsky’s fixative (3% glutaraldehyde 
(EM grade-TAAB, G002), 1% paraformaldehyde in 0.07 M sodium cacodylate (Agar 
Scientific, R1104), pH 7.4) for 2 h at RT. For analysis of retinal vessels, mice were 
perfused with Karnovsky’s fixative. For this, mice were first anaesthetised with a 100 l 
intraperitoneal injection of Euthatal (contains 20% w/v sodium pentabarbitone BP, 
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Merial Animal Health Ltd) and the chest cavity opened. The descending aorta was 
clamped, an incision was made in the right ventricle and a shunt inserted. Karnovsky’s 
fixative was pumped through the shunt, and into the head of the mouse via the right 
ventricle. The right aorta was cut open, and approximately 20 ml of fixative was 
pumped into the right ventricle until the fluid from the right aorta ran clear. Perfused 
eyes were enucleated and immersed in Karnovsky’s fixative for a further 2 h at RT. 
Eyes were washed with 0.1 M cacodylate and the lens was removed by cutting a small 
hole into the cornea. 
 
2.4.2. Embedding 
Eyes were osmicated in 1% osmium tetroxide (Agar Scientific, R1015) - 0.1 M 
cacodylate in the dark for 2 h on ice then washed twice with 0.1 M cacodylate. Eyes 
were dehydrated in successive washes of 70%, 90% and 100% ethanol for 15 min in 
each wash with two 100% washes followed by two 100% propylene oxide (Agar 
Scientific, R1080) washes. Eyes were immersed in a 1:1 mixture of propylene oxide and 
araldite resin (50% dodecenyl succinic anhydride (Agar Scientific, R1051) 40% Araldite 
CY212 (Agar Scientific, R1040) 1.6% DMP30 (TAAB, D032)) overnight at RT. The 
following day, eyes were placed in fresh 100% araldite resin in open tubes and the 
resin replaced after 3-4 h for a further 3-4 h. Eyes were transferred to fresh 100% 
araldite resin and polymerised by baking overnight at 60°C. 
 
2.4.3. Semithin sections and imaging 
Eyes were sectioned and stained by Robin Howes of the electron microscopy 
department at The Institute of Ophthalmology, UCL.  Semithin resin sections of 2 m 
were cut on a Leica ultracut S microtome with a diamond knife through the optic 
nerve. Semithin sections were stained with 1% toluidine blue in 1% borax, 50% ethanol 
for 30 s, washed in 50% ethanol then dried at 60°C for 10 min. Sections were dried and 
mounted in DPX resin (Agar Scientific, R1340). Phase contrast images of semithin resin 
sections were obtained using a 20X objective on an inverted Leica DMIL microscope. 
Digital images were captured with a Leica DC200 digital camera. Density of nuclei in 
the ONL was quantified by manual counting. 
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2.4.4. Ultrathin sections and imaging 
Eyes were sectioned and stained by Robin Howes of the electron microscopy 
department at The Institute of Ophthalmology, UCL. Ultrathin resin sections of 70-80 
nm were cut on a Leica ultracut S microtome with a diamond knife through the optic 
nerve. Sections were stained for 10 min with lead citrate (1.33 g lead nitrate (EM 
grade, TAAB, L019), 1.76 g trisodium citrate in 8 ml 1 M sodium hydroxide and 42 ml 
deionised water). Sections were imaged on a Joel 1010 transmission electron 
microscope at 1500X magnification and digital images were taken using a Gatan Orius 
SC1000B CCD camera.  
 
2.4.5. Organelle distribution analysis 
Organelle distribution was analysed in transmission electron micrographs without a 
nucleus. Mitochondria were identified by their characteristic internal membraneous 
stacks, and melanosomes by their uniform electron dense appearance. The distance 
from the RPE basal lamina to the centre of each organelle was measured using Image J 
software (Rasband, 2011). Over 200 mitochondria and 300 melanosomes were 
quantified from two mice in each group. 
 
2.5. Protein analysis 
2.5.1. Immunohistochemistry 
Sections and flatmounts were imaged using a confocal laser scanning microscope, LSM 
710 and ZEN software (Carl Zeiss Inc.). 
 
2.5.1.1. Tissue sections 
Upon recovery, eyes were immediately immersed in 4% paraformaldehyde (PFA)-PBS 
for 10 min at RT. A small hole was made into the cornea to enable removal of the lens 
and vitreous humour. Eyes were further fixed in 4% PFA-PBS for 2 h at RT or overnight 
at 4°C. Eyes underwent sucrose infiltration (30% sucrose-PBS) overnight at 4°C. Eyes 
were embedded in OCT embedding matrix (Raymond A Lamb, LAMB-OCT) and frozen 
on dry ice then initially stored at -20°C and subsequently at -80°C. 12 m sections were 
cut on a cryostat (CM 1850, Leica Microsystems) at -20°C and adhered to superfrost 
adhesion slides (VWR International, 631-0446). Sections were stored in a sealed box at 
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-80°C. Prior to staining, slides were thawed to RT in the sealed box, removed and dried 
for a minimum of 2 h under a fan at RT.        
                             
Prior to staining, sections were surrounded with wax (Pap-pen, VWR, 720-0169) to 
prevent dehydration of sections during long incubation times. Sections were blocked in 
500 l blocking/permeabilising solution (PBS - 5% normal donkey serum, 1% bovine 
serum albumin (BSA), 0.5% Triton, 0.12% NaN3) for a minimum of 1 h at RT. Primary 
antibodies were diluted according to Table 2.2 in blocking/permeabilising solution, 200 
l added per slide and incubated overnight at 4°C. As a primary antibody control, non-
specific IgG antibodies which matched the species of the primary antibody were 
applied to sections in the same fashion as the primary antibody. As a secondary 
antibody control, sections were also incubated with blocking/permeabilising solution 
containing no antibody. The following day, slides were washed 3 x 5 min in washing 
buffer (PBS-0.1% Tween). Fluorophore-conjugated secondary antibodies were diluted 
according to Table 2.2 in blocking/permeabilising solution, 200 l added per slide and 
incubated for 1 h at RT in the dark. As a control, secondary antibodies were applied to 
sections which had not been stained with primary or non-specific antibody. Slides were 
washed 3 x 5 min in washing buffer and incubated with 4’,6-diamidino-2-phenylindole 
(DAPI, 1 g/ml) for 2 min at RT. Slides were washed 2 x 5 min in PBS and mounted with 
VECTASHIELD® mounting medium (Vector Labs, H-1000) and cover slips.  
 
2.5.1.2. Flatmounts 
Eyes were fixed briefly for 5 min in 2% PFA-1.5X PBS before dissection in 2X PBS. 
External muscle and the optic nerve were trimmed to aid flattening and the eye was 
cut in half with the incision following posterior to the ora-serrata. The anterior eyecup, 
lens and vitreous humour were discarded. The neuroretina was carefully peeled away 
from the RPE using forceps and detached at the optic nerve head. 4-6 incisions 2/3 in 
towards the centre were made in order to enable flattening. After PBS aspiration, 
flattened neuroretinas were re-fixed and stored in ice cold methanol at -20°C. 
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All incubation steps were carried out on an orbital shaker. Prior to staining, 
neuroretinas were re-fixed in 4% PFA-PBS for 2 min at RT, washed in 2X PBS and 
blocked for 1 h at RT (blocking/permeabilising solution: 2X PBS, 3% Triton, 1% BSA-
fraction V, 0.5% Tween, 0.1% NaN3). Primary antibodies were made up in 
blocking/permeabilising solution according to Table 2.2 100 l of primary antibody was 
applied to each neuroretina in a 96 well plate (Nunc) overnight at RT. The following 
day, neuroretinas were washed 3 x 10 min in blocking/permeabilising solution. 
Fluorophore-conjugated secondary antibodies were made up in blocking/ 
permeabilising solution according to Table 2.2 and 100 l applied for 2 h at RT. 
Neuroretinas were washed 2 x 10 min in blocking/permeabilising solution and  for 10 
min in 2X PBS. Neuroretinas were re-fixed in 4% PFA-PBS for 10 min at RT and washed 
2 x 5 min in 2X PBS. Neuroretinas were mounted on slides in MOWIAL® mounting 
medium (see following Section). 
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2.5.1.2.1. Mowial mounting medium 
2.6 g MOWIAL® (Calbiochem, 475904) was added to 6 g glycerol and mixed for 1 h at 
RT on a roller. To this, 6 ml of deionised water was added and mixing continued 
overnight at RT. The following day, 12 ml 0.25 M Tris-HCl (pH 8.5) was added and the 
mixture heated to 50 C, for 5 h shaking every 30 min. Mountant was stored in aliquots 
at -20 C. 
 
2.5.2. Protein isolation  
Unfixed eyes were immediately dissected as in Section 2.5.1.2 The neuroretina and 
remaining eyecup were separately immersed in 200 l 2X SDS-PAGE sample buffer 
(described in Section 2.1.3) and rotated overnight to disrupt the tissue. The following 
day, the neuroretina lysate was passed through a 21G needle and the eyecup removed 
leaving the pigmented lysate of the RPE/choroid remaining. Samples were heated to 
95°C for 5 min and stored at -20°C. 
 
2.6. Gene expression analysis 
2.6.1. RNA isolation 
Isolation of RNA for microarray analysis and subsequent analysis of data was 
performed in collaboration with Dr. Carsten Faber (University of Copenhagen).  
 
All surfaces and dissection equipment were thoroughly cleaned with RNaseZap® 
(Ambion Inc, AM9780) and rinsed with 0.1% diethylpyrocarbonate treated water. 
Dissection of each eye was within 5 min of enucleation. Eyes were dissected as 
detailed in Section 2.5.1.2. 
 
For microarray analysis, neuroretinas were removed and placed in RNAlater®, stored 
at 4°C overnight and on the following day RNAlater® was removed and the tissue 
frozen at -80°C. Thawed neuroretinas were treated with TRIzol® reagent (Invitrogen, 
15596-026) for RNA isolation and passed through a QIAshredder (QIAGEN, 79654). 
 
RNA isolation from RPE was tested by applying TRIzol® reagent to the remaining 
eyecup in either an Eppendorf tube which was rotated for 10 min or on a petri dish 
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where the pigmented cells were scraped off using a 21 G needle. For microarray 
samples, RPE/choroid RNA was isolated using the scraping method. RNA and protein 
isolation from TRIzol® reagent for both RPE/choroid and neuroretina samples was 
performed according to the manufacturer’s protocol.  
 
Isolated RNA underwent a clean-up procedure using the RNeasy kit (QIAGEN, 74104). 
RNA was eluted in 30 l RNase free water. DNA was degraded by treating each 30 l 
sample with 1 l of amplification grade DNase I (Invitrogen, 18068-015) and 3.44 l of 
the accompanying buffer (200 mM Tris-HCl (pH 8.4), 20 mM MgCl2 , 500 mM KCl) and 
incubating for 15 min at RT. The reaction was stopped by addition of 1 l of 25 mM 
EDTA (pH 8.0) and incubating for 15 min at 60°C. RNA was stored at -80°C. 
 
For real-time quantitative polymerase chain reactions (RT qPCR), RNA was isolated 
using the RNEasy kit. After dissection, the neuroretina was placed in 350 l of buffer 
RLT. To the remaining eyecup, 350 l buffer RLT was applied and the RPE/choroid 
scraped off using a 21 G needle. RNA was isolated following the manufacturer’s 
protocol. 
 
2.6.2. Reverse transcription of RNA 
RNA concentration was quantified using a NanoDrop spectrophotometer (Thermo 
Scientific). 350 ng of RPE/choroid or 600 ng of neuroretina RNA was used for reverse 
transcription into complementary DNA (cDNA) using the QuantiTect Reverse 
Transcription kit (QIAGEN, 205311) following the manufacturer’s protocol. Briefly, 
genomic DNA was eliminated in a 5 min reaction followed by reverse transcription 
using an reverse transcription primer mix (containing an optimised blend of oligo-dT 
and random primers) for 15 min at 42°C followed by a 3 min inactivation step at 95°C.   
 
2.6.3. Real-time quantitative polymerase chain reactions 
RT qPCR reactions were set up on ice, in triplicate, using Power SYBR® green 
mastermix (Applied Biosystems, 4309155). Each 25 l reaction contained 12.5 l 
mastermix (SYBR® green 1 dye, AmpliTaq Gold® DNA polymerase, dNTPs, dUTPs, 
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passive reference and optimised buffers), 1.5 l forward primer (5 M), 1.5 l reverse 
primer (5 M) (Table 2.3), 1 l cDNA template and 8.5 l RNase free water.  
 
 
 
Samples were run on 7900HT Fast Real-Time PCR System (Applied Biosystems) using 
the following programme: 
1. Denaturation at 95°C for 10 min 
2. 40 cycles of denaturation at 95°C for 15 s > amplification at 60°C for 1 min  
3. 1 cycle of denaturation 95°C for 15 s > amplification 60°C for 15 s 
4. Denaturation at 95°C for 15 s  
Dissociation curves were checked after each run to ensure only one peak was present. 
Raw fluorescence data and cycle information were imported into Data analysis for 
real-time PCR (DART-PCR) version 1.0 (Peirson et al., 2003) in an excel workbook. This 
programme converts raw data into relative expression values (R0) after the following 
steps:  
1. Groups and triplicates are assigned 
2. Samples which are outliers for amplification efficiency are removed 
3. Amplification efficiency and threshold set 
Relative expression of the gene of interest was normalised to β-actin as an internal 
control. 
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2.6.4. Microarray analysis 
Quality control and processing of RNA, and statistical analysis, was performed by the 
UCL Genomics Facility. RNA was isolated from Cfh-/- and C57Bl/6 mice of 7-8 weeks and 
1 year 140 days ± 6 days (according to Section 2.6.1). 
 
2.6.4.1. Quantitative and qualitative analysis of RNA 
RNA quality and quantity were assessed using Agilent RNA 6000 pico and nano kits 
(Agilent, 5067-1511/3) which use a fluorescent dye that intercalates with nucleic acids 
that are subsequently separated by electrophoresis in an Agilent Bioanalyzer 2100. 
RPE/choroid RNA was loaded onto pico microfluidic chips (detection of RNA > 50 pg/ l) 
and neuroretina RNA onto nano microfluidic chips (detection of RNA > 25-500 ng/ l) 
and the manufacturer’s protocol followed.  
 
2.6.4.2. Linear amplification of RNA 
RPE/choroid RNA quantity was below the minimum requirement for microarray 
analysis (1 g) therefore it was linearly amplified using an Ovation WGA amplification 
kit according to the manufacturer’s protocol (NuGEN Technologies, 6100-012). This kit 
averages a 15,000 x linear amplification of all mRNA. Amplification is initiated both at 
the 3' end and randomly throughout the whole mRNA transcript to enable 
amplification of non-poly (A) transcripts and compromised RNA samples.  
 
2.6.4.3. Amplification, fragmentation and terminal labelling 
RNA underwent sense target labelling assay prior to hybridisation to Affymetrix Mouse 
Gene 1.0 ST Array GeneChips® (Affymetrix, 9011680). Each GeneChip® comprised of 
more than 750,000 unique 25-mer oligonucleotides representing more than 28,853 
gene-level probe sets.  Each probe set contains ≈ 27 probes spread across the full 
length of the gene. 
 
2.6.4.4. Statistical analyses of microarray data 
After general array quality control and data export, the data were normalised using 
robust multiarray average (RMA) and imported into Partek software. Array data were 
then checked for any outliers and overall grouping/separation using principal 
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component analysis (PCA), and signal histograms. ANOVA analysis of data generated a 
standard p-value. The p-values were adjusted using the Benjamini & Hochberg method 
to reduce false positives due to multiple testing. Comparison of the data was carried 
out using a false discovery rate of ≤ 0.05 to create gene lists which showed significant 
differentially expressed genes and exons between the different groups. 
 
2.6.4.5. Pathway analysis 
Ingenuity Pathway Analysis® (IPA) software was used to analyse the lists of genes 
which were identified as being significantly differentially expressed between groups. 
This identified whether there were any direct or indirect links between genes in each 
list to a single pathway. It also identified which canonical and cellular functions were 
most affected in each gene list.  Some genes in each list were classified as ‘unmapped’ 
and were therefore excluded from the analysis. This work was carried out using a free 
trial licence registered to Jennifer Williams. 
 
2.7. Statistical tests 
Standard deviations (S.D.) and unpaired, two-tailed, Student t-tests were calculated 
using Microsoft® Excel. One-way Analysis of Variance (ANOVA) tests were calculated in 
GraphPad Prism® software. Spearman’s Rank correlation coefficient was calculated 
using the following formula:  1 – (6Σd2/n2-1), where Σd = sum of the differences and n = 
number of data points. Differences are calculated by ranking each data set separately 
in numerical order, data points are given a value dependent on their rank (e.g. 1-8 if n 
= 8). The difference in values assigned to each comparable data point in each data set 
is the difference. 
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Chapter 3: Results 
A Study of the Secretion of Complement Factor H from Retinal Pigment 
Epithelial Cells 
Since the discovery of complement proteins in drusen (Mullins et al., 2000), it has been 
speculated that complement plays a pathogenic role in AMD, though whether it had a 
direct or indirect role was undecided. In 2005 however, four separate studies 
identified the same SNP in CFH that confers increased risk for AMD (Edwards et al., 
2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005) (see Section 1.4.3.2). 
Together these studies suggested that up to 50% of all AMD cases could be linked to 
this SNP in the CFH gene. Previous to this, most research into CFH focused on its role in 
kidney diseases where its dysfunction or absence had been shown to be one of the 
causes of DDD and aHUS (Zipfel et al., 2006). 
 
The largest pool of CFH is in the blood where in humans the concentration ranges from 
120-790 g/ml (see Section 1.2.3). Most serum CFH is made by the liver and, via the 
blood, it helps to protect against inappropriate complement attack for all organs and 
tissues it has access to. In addition to the CFH provided from the blood, most organs 
produce their own CFH; this is thought to increase local concentrations to offer 
additional protection against uncontrolled complement activation.  
 
The eye is capable of producing its own CFH and in contrast to other organs it may 
depend on this resource more heavily than the supply from the blood because of the 
blood-retinal barrier which restricts the movement of proteins from the blood into the 
retina. In human eyes CFH protein expression has been reported in several tissues 
including the optic nerve, lens, RPE, ciliary body, sclera and retina (Mandal and 
Ayyagari, 2006). RPE cells are thought to be the main producers of CFH in the eye, as 
mRNA expression is higher than in any other ocular cell type (Hageman et al., 2005). 
 
The RPE is considered central to the pathogenesis of AMD since it is believed to be 
partly responsible for the development of drusen, and several of its key functions in 
maintaining homeostasis in the retina become dysregulated in AMD.  Since both CFH 
and the RPE are central to the pathogenesis of AMD and the RPE is thought to be the 
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major local producer of CFH in the eye, the first aim of this study was to investigate the 
secretion of CFH from the RPE. Since 2005 only a handful of publications have explored 
the secretion of CFH from RPE cells (An et al., 2006; Chen et al., 2007; Yu et al., 2007; 
Kim et al., 2009; Juel et al., 2011; Lau et al., 2011). This chapter describes studies of 
CFH secretion from RPE cells in culture.  
 
3.1. Optimisation of ARPE19 secretion assay for the quantification of CFH 
In order to quantify CFH secretion from RPE cells in culture the RPE cell line ARPE19 
was chosen as a model cell line for optimising the secretion assay. The quantification 
of CFH from ARPE19 culture supernatants was complicated by the presence of CFH in 
FCS used to supplement DMEM for culturing ARPE19 cells. ARPE19 cells were 
therefore grown to confluency in the presence of serum, but after thorough washing 
with PBS, secretion assays were performed in serum-free DMEM. Culture supernatants 
were collected from ARPE19 cells maintained for 72 h in serum-free DMEM and the 
proteins were resolved by SDS-PAGE and western blotted for CFH. CFH was not 
identified in the culture supernatant (data not shown), most likely because it was 
below the threshold for detection. Therefore, in order to maximise the protein loading 
from each culture supernatant sample, proteins were first concentrated by 
precipitation. Two protein precipitating agents, acetone and TCA were tested. A 
culture supernatant sample collected from ARPE19 cells maintained in serum-free 
DMEM for 24 h was divided equally and precipitated with either acetone or TCA.  
Subsequent SDS-PAGE and western blotting for CFH revealed that TCA was more 
efficient at precipitating CFH than acetone (Figure 3.1).  TCA was therefore chosen as 
the precipitating agent for concentrating proteins to enable CFH quantification from 
the dilute culture supernatants. This result also confirmed that ARPE19 cells secrete 
CFH, consistent with Juel et al. (2011), who were the first to report this. 
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3.2. Serum starvation causes a similar pattern of CFH secretion in both ARPE19 and 
primary porcine RPE cells 
It was important to examine the consequences of serum starvation on CFH secretion in 
order to interpret the effects of any agonist treatment applied to the cells in future 
experiments. Two RPE cell types were used, the RPE cell line ARPE19 and primary RPE 
cells isolated from porcine eyes. RPE cells were cultured in DMEM containing serum, 
until they reached confluency. Confluent cells were used to limit the complication of 
cell growth over the time of the assay, to improve the ability of the cells to withstand 
serum withdrawal and to represent the in vivo situation where the RPE exists as a 
confluent monolayer. RPE cells were washed twice in PBS in order to remove any 
traces of CFH in the media. In a 6-well plate, 4 wells were treated with serum-free 
DMEM in an ‘accumulative’ fashion whereby medium was removed after 2, 4, 6 and 8 
h. In order to analyse CFH secretion in between each time point, one well was treated 
‘serially’, whereby fresh serum-free DMEM was added and removed every 2 h up until 
8 h. There were no visible signs of cell stress or change in cell density after 8 h of 
serum starvation (Figure 3.2A).  
 
Western blot analysis of ARPE19 culture supernatants showed that CFH accumulated 
in the media over the 8 h period (Figure 3.2B). Serial ARPE19 samples revealed that 
CFH was secreted in increasing amounts with each change of media; this peaked at 6 h 
and subsequently decreased. Similarly, CFH secreted by primary porcine RPE 
accumulated in the media over 8 h and had a comparable secretory pattern to ARPE19 
cells when the media were changed serially.   
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By densitometric analysis of each band, CFH was quantified and an average of the 
mean pixel intensity (MPI) of ARPE19 and primary porcine RPE bands were plotted 
against time (Figure 3.2C). The graph shows that the relationship between the 
accumulation of CFH and time was largely linear between 4-8 h. The increase in CFH 
secretion from 2-4 h does not fit this linear relationship, between these two time 
points the gradient increased, indicating an increased rate of CFH secretion between 
these time points. The relationship between time and CFH secretion from the serial 
samples was linear up until 6 h but after this CFH secretion decreased. This decline in 
the capacity to secrete CFH after 6 h was likely caused by the sequential serum-free 
media changes applied to the serial samples since this decrease was not observed in 
RPE cells treated in an accumulative fashion.  
 
At the end of the secretion assay, the ARPE19 cells which had been treated with 
DMEM in an accumulative fashion were lysed in SDS-PAGE sample buffer. Cellular 
proteins were resolved by SDS-PAGE and western blotted for CFH. Protein bands were 
visible at approximately 130 kDa and 200 kDa but no bands of 155 kDa were identified 
(Figure 3.2D). This suggests that CFH secreted into the media did not adhere to the 
cells, as this would have been expected to yield a similar sized band to the CFH present 
in the culture supernatant. The intensity of the 130 kDa and 200 kDa bands did not 
change at the different time points of the accumulative samples. Other reports where 
CFH was quantified from cell lysates used a different antibody to the one used in these 
experiments and this may account for the difference in band sizes observed. 
 
In summary, these results show that serum starvation causes similar patterns of CFH 
secretion from both ARPE19 and primary porcine RPE cells. A Spearman’s rank 
statistical test for non-parametric statistical dependence between two variables 
showed a positive correlation of 0.7. Since ARPE19 cells behaved similarly to primary 
porcine RPE, we were confident in using ARPE19 cells as a model for RPE secretion of 
CFH in further experiments. 
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3.3. Alternative methods of concentrating CFH are not as efficient as TCA 
precipitation for CFH quantification 
The rise and fall of CFH secretion by RPE cells in Figure 3.2 could have several 
explanations. The removal of serum may stimulate a burst of secretion as a stress-
response which peaks at 4-6 h. To circumvent the possibility of a stress-response 
induced by serum withdrawal, we tested the secretion of CFH in a serum-free 
supplemented medium, X-VIVO™ 15, which does not contain CFH, and is specifically 
designed to support cells in a serum-free environment (Juel et al., 2011). However, X-
VIVO™ 15 contains added proteins which when precipitated with TCA formed an 
insoluble protein pellet. In order to use X-VIVO™ 15 medium in secretion assays, CFH 
would therefore have to be isolated from the culture supernatants using a method 
that avoided generating an unworkable protein pellet. In principle this could be 
achieved by performing an ammonium sulphate cut, where proteins of different 
solubility are precipitated at different salt concentrations. 
 
To test whether this technique would be suitable for the isolation of CFH, an 
ammonium sulphate cut was performed on culture supernatants from ARPE19 cells 
cultured in serum-free DMEM for 72 h. Ammonium sulphate was added in increasing 
concentrations of 29%, 55%, 62%, 67% and 71% to the same sample in a stepwise 
fashion and the precipitates removed at each step. The largest yield of CFH came from 
the 29% ammonium sulphate cut (Figure 3.3A), which was similar to the amount 
recovered in a comparable sample precipitated with TCA.  However, repeating the 
experiment with a lower starting concentration of ammonium sulphate and increasing 
in smaller steps (5%, 14%, 25%, 32%, 41% and 50%), appeared to reduce the efficiency 
of CFH precipitation (Figure 3.3B). In practise, we concluded that this was not an 
accurate method of obtaining CFH protein for absolute quantification.  
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As an alternative to protein precipitation, we next attempted to exploit the binding 
properties of CFH in order to isolate the protein from X-VIVO™ 15. CFH is known to 
bind glycosaminoglycans such as heparin (Blackmore et al., 1996), suggesting that 
heparin-agarose beads could therefore be used for this purpose. Supernatants from 
ARPE19 cells cultured in either serum-free DMEM or X-VIVO™ 15 for 48 h were mixed 
with heparin-agarose beads in order to isolate CFH. After 3.5 h of incubation, the 
beads were removed from the culture supernatants by centrifugation and the isolated 
proteins were recovered from the beads by boiling in SDS-PAGE sample buffer. 
Western blot analysis of the isolated proteins showed that CFH recovery from ARPE19 
culture supernatants was successful (Figure 3.4A). A similar level of CFH secretion was 
seen using ARPE19 cells whether cultured in either serum-free DMEM or X-VIVO™ 15. 
CFH was not present in DMEM or X-VIVO™15 media itself which had not been in 
contact with ARPE19 cells (Figure 3.4A).  
 
In order to determine whether heparin-agarose was efficient at isolating all the CFH 
present in the samples, the culture supernatants, post heparin-agarose bead 
incubation, were precipitated with TCA. TCA precipitated proteins were western 
blotted for CFH (Figure 3.4B). The DMEM sample showed a significant CFH band 
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indicating that heparin-agarose did not isolate all the CFH from the sample. The X-
VIVO™ 15 sample only had a faint CFH band which would suggest that the vast 
majority of CFH was recovered. However, when the X-VIVO™ 15 sample was treated 
with TCA an insoluble pellet formed, making subsequent analysis by SDS-PAGE and 
western blotting impossible. These results indicate that under these conditions, 
efficient CFH isolation by heparin-agarose for quantification was not possible.  
Nevertheless, it could be that by increasing the amount of heparin-agarose beads or 
incubation time, or altering other parameters, this method could be optimised to 
increase the efficiency of CFH isolation. But taking into consideration the large volume 
of heparin-agarose beads that would be required, long incubation times and inefficient 
CFH isolation, this method was not considered suitable to enable robust quantification 
of secreted CFH. It was therefore decided to perform RPE secretion assays in serum-
free DMEM rather than X-VIVO™ 15. 
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3.4. Secretion of CFH from ARPE19 cells is similar whether cultured in 10% or 1% FCS 
Results from our Institute have suggested that ARPE19 cells become more quiescent 
and ‘RPE-like’ when the serum concentration is reduced to 1% compared to 10% 
(personal communication, Ahmado A.). On account of these observations we 
speculated that the culture conditions pre serum starvation could affect CFH secretion. 
We therefore performed an 8 h secretion assay, as described in Section 3.2, on ARPE19 
cells that had been grown for a minimum of two weeks in either 10% or 1% FCS. No 
differences were observed in cell density or morphology when the cells were visualised 
using phase contrast microscopy (data not shown). In order to control for precipitation 
efficiency, goat IgG was added to the collected culture supernatants prior to 
precipitation with TCA. CFH bands were quantified by calculating the MPI, and 
normalised to the MPI of their respective goat IgG bands. Even though the same 
amount of goat IgG was added to each sample it was clear from the densities of the 
IgG bands on the western blot that protein recovery was variable (Figure 3.5A). This 
may have been the result of protein lost during washing, or different precipitation or 
transfer efficiencies, and it showed the importance of normalising CFH secretion data 
to IgG bands. 
 
Quantification and normalisation of the CFH bands from three experiments showed 
that the pattern of CFH secretion was similar between ARPE19 cells cultured in 10% 
and 1% FCS (Figure 3.5B). CFH secretion from the serial well showed that with 
successive media changes less CFH was secreted at later time points, similar to 
previous results which showed a peak of secretion from the serial well at 4-6 h. The 
results from the accumulative samples were consistent with previous results (Figure 
3.2) in which CFH accumulated rapidly from 2-6 h, and more slowly thereafter. 
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CFH secretion was on average higher from ARPE19 cells cultured in 1% FCS than in 10% 
FCS in serial samples. However, unpaired Student t-tests for each time point revealed a 
significant difference in CFH secretion at the serial 2 h time point only (p = < 0.01). This 
difference may reflect CFH secretion prior to serum starvation which could have been 
higher due to the lower concentration of CFH in 1% FCS supplemented DMEM. 
However, CFH secretion from accumulative samples showed higher CFH secretion from 
cells cultured in 10% FCS. 
 
3.5. CFH secretion pattern from ARPE19 cells over an extended time course 
In order to address whether the drop in CFH secretion after 4-6 h was a consequence 
of stress caused by serum withdrawal, we extended the time course of the secretion 
assay up to 72 h with time points at 0, 8, 24, 48 and 72 h. The assay was carried out in 
the same manner as the 8 h assay with culture supernatants removed in both an 
accumulative and serial fashion.  
 
No differences were observed in cell density or morphology when ARPE19 cells were 
visualised using phase contrast microscopy after 72 h in serum-free media (data not 
shown).  Results from four experiments showed that the ARPE19 cells continued to 
secrete CFH after more than 8 h in serum-free conditions (Figure 3.6A). The normalised 
accumulative data show that CFH accumulated in the culture supernatant over time in 
an approximately linear manner (Figure 3.6B). Analyses of the serial samples revealed 
that CFH secretion was maximal in the second 24 h period (48 h time point). However, 
note that the serial 24 h time point should be regarded as 16 h of actual secretion 
time. When this is added to the 8 h serial time point the total value is similar to the full 
24 h value observed in the accumulative well. These results suggest that ARPE19 cells 
secrete CFH in serum-free conditions for at least three days and perhaps longer.  
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3.6. The effect of inflammatory cytokines on CFH secretion 
Consistent with the involvement of complement in inflammatory reactions the 
expression of complement proteins is influenced by the cytokine environment. The 
CFH gene promoter region contains an IFN  responsive site and acute phase response 
elements which indicate that pro-inflammatory cytokines can regulate gene expression 
(Section 1.2.3). Indeed, IFN  has been shown to stimulate CFH expression in several 
cell types (Lappin et al., 1992) and this has been shown to be mediated by the 
activation of the transcription factor, signal transducer and activator of transcription 1 
(STAT1) in RPE cells (Wu et al., 2007). Other pro-inflammatory cytokines such as IL-1  
(Halme et al., 2009) and TNFα (Katz and Strunk, 1989; Thomas et al., 2000) have also 
been shown to stimulate CFH expression although reports are not consistent between 
groups and different cell types (Schlaf et al., 2002; Timar et al., 2006). RPE cells express 
soluble and cell surface cytokine receptors and it is well documented that cytokines 
influence the expression of many proteins expressed by RPE cells (Holtkamp et al., 
2001; An et al., 2008; Shi et al., 2008). However, only a handful of papers have 
addressed the influence of pro-inflammatory cytokines on CFH secretion by RPE cells, 
and the results of these studies are not all in agreement with one another (Chen et al., 
2007; Wu et al., 2007; Kim et al., 2009; Juel et al., 2011; Luo et al., 2011; Lau et al., 
2011). Given the likely importance of CFH secretion by RPE in AMD, and the conflicts in 
the literature, we therefore tested the effects of three pro-inflammatory cytokines, 
IFN , TNFα and IL-1 , on CFH secretion.  
 
Confluent ARPE19 cells were treated with serum-free DMEM containing 0-200 ng/ml 
of IFN , TNFα or IL-1  and incubated for 8 h. The culture supernatants were 
precipitated with TCA, resolved by SDS-PAGE and western blotted for CFH. TNFα did 
not have a detectable effect on CFH secretion, however both IL-1  and IFN  stimulated 
an increase in CFH secretion (Figure 3.7A). Quantification of the protein bands 
indicated that CFH secretion was enhanced with increasing concentrations of IFN  and 
IL-1  (Figure 3.7B).  
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To address the speed at which ARPE19 cells are able to respond to cytokine 
stimulation, IFN  mediated CFH secretion was tested over an 8 h time course. 
Confluent ARPE19 cells were treated with serum-free DMEM containing either 0 or 
100 ng/ml of IFN . Accumulative samples were taken after 0, 2, 4, 6 or 8 h. The culture 
supernatants were precipitated with TCA, resolved by SDS-PAGE and western blotted 
for CFH (Figure 3.8A). Quantification of the CFH bands showed that ARPE19 cells 
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respond to IFN  within 2 h, and that this response was enhanced at each subsequent 
time point (Figure 3.8B). This indicated that the effect of IFN  was sustained over 8 h 
suggesting that under inflammatory situations where IFN  is present, RPE cells may 
chronically increase the amount of CFH they secrete. In vivo this response would likely 
contribute to protecting the neighbouring photoreceptors and the RPE cells 
themselves from potential damage caused by complement activation during an 
inflammatory event.  
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3.7. ARPE19 cells synthesise CFH de novo under serum-free conditions 
To determine whether the CFH secreted from ARPE19 cells was derived from 
intracellular stores or was synthesised de novo, cycloheximide was added to secretion 
assays. Cycloheximide inhibits the translation of mRNA but does not affect the 
secretion of stored proteins. Confluent ARPE19 cells were serum-starved in DMEM 
either in the presence of 10 μM cycloheximide or the equivalent dilution of DMSO 
(vehicle). Serial and accumulative samples were taken at 0, 2, 4, 6, and 8 h.  
 
Results showed that after 2 h, CFH secretion was markedly inhibited by the presence 
of cycloheximide in the accumulative samples (Figure 3.9A). A Student t-test for each 
time point revealed a significant difference between cycloheximide and vehicle treated 
samples when collected accumulatively. The CFH which was secreted during the first 2 
h may represent release of a small intracellular store, or protein that had been 
translated and was en route to the secretory pathway before incubation with 
cycloheximide. Quantification and normalisation of the CFH bands revealed a small 
increase in CFH in the accumulative samples over time in the presence of 
cycloheximide (Figure 3.9B). This suggests either that ARPE19 cells indeed have a small 
store of CFH which is slowly released over 8 h, or that cycloheximide does not 
completely block mRNA translation. The serial and accumulative results from the 
DMSO controls were largely consistent with previous results. The experiment reveals a 
significant block in CFH secretion in the presence of cycloheximide in comparison to 
control, suggesting that the majority of CFH secretion from ARPE19 cells following 
serum withdrawal is the result of de novo protein synthesis. 
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3.8. Discussion 
The presence of CFH in drusen, the early hallmark of AMD, and the Y402H SNP in CFH 
that is linked to AMD susceptibility together present a strong case for the involvement 
of this protein in the pathogenesis of AMD. The source of CFH in drusen is believed to 
be the RPE because of its close proximity. Both primary isolated mouse and human RPE 
express CFH mRNA (Mandal and Ayyagari, 2006) and it has been suggested that CFH 
transcript levels in RPE are as high as those in the liver (Hageman et al., 2005). 
Although CFH is expressed in a variety of cell types, regulation of CFH expression is 
believed to cell-type specific (Friese et al., 1999). Several factors including cytokines, 
phagocytosis, oxidative stress and co-culture with activated T-cells have been shown to 
alter the expression of CFH by RPE cells (Chen et al., 2007; Wu et al., 2007; Kim et al., 
2009; Juel et al., 2011; Luo et al., 2011; Lau et al., 2011). However, changes in CFH 
mRNA do not always correspond to a change in protein expression as demonstrated by 
Chen et al., (2007) who reported a decrease in Cfh mRNA after IL-6 exposure with no 
subsequent change in CFH protein expression. Taking these points into consideration, 
together with the fact that CFH must be secreted in order for it to carry out its function 
as a regulator of the alternative pathway, we decided to investigate the secretion and 
expression of CFH in RPE cells.  
 
To date there are only six published reports of CFH secretion by RPE cells (An et al., 
2006; Chen et al., 2007; Yu et al., 2007; Kim et al., 2009; Juel et al., 2011; Lau et al., 
2011), of which three have shown that this can be manipulated by exposure to IFN  or 
co-culture with activated T-cells (Kim et al., 2009; Juel et al., 2011; Lau et al., 2011). 
The paucity of literature on this topic, given that it is six years since CFH was linked to 
AMD, may be due to the difficult nature of studying secretion of a protein which is 
itself present in the serum used to culture the cells. An et al., (2006) were the first to 
show that RPE cells are capable of secreting CFH, in experiments in which they used 
stable isotope labelling of amino acids in cell culture. With the limited literature on 
CFH secretion from RPE cells we attempted to develop an in vitro assay in which to 
study CFH secretion. 
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Due to the limited availability of primary human RPE cells, we chose to use the cell line 
ARPE19, which spontaneously arose from RPE cultured from a male donor in the 
University of California (Dunn et al., 1996). Unlike transformed RPE cell lines, ARPE19 
cells retain their normal RPE karyology as well as structural and functional 
characteristics of RPE cells in vivo. However, a study comparing the gene expression of 
ARPE19 cells to primary human RPE, showed that ARPE19 cells exclusively express 9 
genes which are not expressed by primary human RPE, and conversely do not express 
35 genes which primary human RPE cells do express (Cai and Del Priore, 2006). These 
genes represent less than 1% of all the genes expressed by either cell type, and of 
these none were complement genes. However, this study also showed that almost 2% 
of the genes expressed were either up or down-regulated >3 fold in ARPE19 cells 
compared to primary human RPE, and that these could be sorted into two distinct 
hierarchical clusters. Although our results show that in serum-free conditions ARPE19 
cells secrete CFH in a similar manner to primary porcine RPE, the limitations of using a 
cell line must be considered when extrapolating these results to an in vivo scenario.  
 
Developing this assay presented several challenges. Firstly CFH is present in FCS which 
is routinely used to culture RPE cells in vitro. Our CFH antibody recognised bovine CFH, 
the presence of which in the media of secretion assays masked any endogenous CFH 
secreted by the cells even when FCS was lowered to 1% of the total volume. A second 
challenge was accurately measuring the low levels of CFH secreted into the media. We 
dealt with this problem by precipitating spent media. Other techniques such as 
enzyme-linked immunosorbent assay may have also been applied, however this would 
have required species-specific CFH antibodies, which we were unable to identify from 
commercial sources.  
 
Another consideration was the choice of culture conditions for the ARPE19 cells. Tian 
et al., (2005) showed that serum added to the culture media for ARPE19 cells caused 
more changes in gene expression than when the cells were in serum-free conditions as 
compared to gene expression by primary RPE. Here we observed that culturing ARPE19 
cells in low or high serum did not significantly affect the overall secretion pattern of 
CFH in response to serum starvation. 
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Upon initial removal of serum from cultured RPE cells, we observed secretion of  CFH 
within 2 h. In serially collected samples, where precipitation efficacy was controlled for 
by spiking the samples with IgG, CFH secretion diminished with each serial change of 
media. However, the accumulative data showed that CFH secretion continued after 2 h 
since CFH levels accumulated in a largely linear fashion over an 8 h period. Therefore 
the drop in CFH secretion in serial samples after 2 h is most likely due to serial media 
changes causing stress to the cells. The extended time course revealed similar results 
where CFH accumulated over a 72 h period in accumulative samples but serial samples 
showed a failure to secrete CFH after the third replenishment of media. The 
accumulative data suggest that CFH is constitutively secreted since CFH levels did not 
plateau by 72 h. If CFH secretion is not constitutive it would be interesting to test 
whether serum depleted of CFH initiates the same secretory pattern as complete 
serum removal. As CFH depleted serum is commercially unavailable, we attempted to 
deplete FCS of CFH by separation through a heparin column, however complete 
removal was unachievable due to the high concentration of CFH in serum. 
 
The peak in CFH secretion seen after serum removal is largely the result of de novo 
synthesis since it was largely abrogated in the presence of cycloheximide. The CFH 
secretion measured after 2 h in cycloheximide could represent release of a small store 
of CFH within the RPE, or may be protein that had already been translated and was 
being processed in the secretory pathway, before the cycloheximide took effect.  
 
Chen et al., (2007) were the first to investigate the effect of pro-inflammatory 
cytokines on CFH expression by RPE cells. They showed that TNFα significantly 
decreased the expression of CFH expression whereas IL-1, IL-4, IL-6 and IFN  had no 
effect. Four further studies generated opposing data, that IFN  stimulates both 
expression and secretion of CFH by RPE cells (Wu et al., 2007; Kim et al., 2009; Luo et 
al., 2011; Lau et al., 2011). Our results also disagree with those of Mei et al., (2007) in 
that we observed that TNFα had no effect on CFH secretion and that IFN  and IL-1  
were capable of stimulating CFH secretion. A significant difference in experimental 
strategies is that Mei et al., (2007) conducted their studies on a mouse RPE line. Thus, 
it is also possible that in addition to being cell type specific, the regulation of CFH by 
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pro-inflammatory cytokines is species specific too. Our results should be repeated in 
primary cells to show that this is not a cell-line specific effect due to differences in 
transcription such as those shown by Cai et al. (2009). One of the 90 genes they 
showed to be differentially expressed was the transcription factor, STAT1, whose 
expression was 3.2 fold increased in native human RPE cells compared to ARPE19 cells. 
STAT1 has been shown to mediate IFN  enhanced CFH secretion by RPE (Wu et al., 
2007) and therefore ARPE19 cells may be less responsive to IFN  compared to primary 
cells.  
 
In conclusion, we have shown that ARPE19 cells secrete de novo synthesised CFH for at 
least 72 h in serum-free conditions. The secretory pattern suggests that RPE cells 
secrete CFH constitutively but that this secretion may be enhanced in inflammatory 
conditions perhaps to strengthen their own protection and that of their surroundings 
from complement bystander damage. 
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Chapter 4: Results 
Characterisation of the Retina in 7-8 week and 1 year old Cfh-/- Mice 
Previous work from our group has shown that CFH is required for normal visual 
function in 2 year old mice (Coffey et al., 2007). In the absence of CFH, mice have 
reduced visual acuity and a diminished rod photoreceptor response. Subretinal C3 and 
autofluorescent deposits were shown to accumulate but electron-dense material 
decreased. Bruch’s membrane became thinner and there was disorganisation of RPE 
organelles and rod photoreceptors. However, it is unknown when these functional and 
anatomical abnormalities begin in Cfh-/- mice. This chapter characterises the retina of 
Cfh-/- mice at 7-8 weeks and 1 year and investigates whether any of the abnormalities 
reported at 2 years are evident at 1 year or earlier. 
 
4.1. Loss of CFH leads to a reduction in photoreceptor density at 1 year 
First we assessed whether the loss of CFH caused any morphological disorganisation in 
the retinas of young or 1 year Cfh-/- mice. We compared Cfh-/- mice at 7-8 weeks 
(young) and 1 year (aged), and used wild-type age-matched controls to monitor 
changes associated with normal ageing. Semithin resin sections were cut from fixed 
eyes in all four groups and stained with toluidine blue (Figure 4.1A-D). We observed a 
greater tendency for photoreceptor detachment in the 1 year Cfh-/- samples than in 
aged-matched wild-type samples (data not shown) and that photoreceptor density 
appeared reduced in comparison to all other groups. Quantification of the nuclei in the 
ONL revealed that there was a significant reduction in their number with age in both 
wild-type and Cfh-/- mice (Figure 4.1E). Nuclei density in the ONL was not significantly 
different between young wild-type and Cfh-/- mice however it was significantly reduced 
in the 1 year samples. In addition to the ONL, the OPL and INL of the 1 year Cfh-/- 
samples appeared less dense than those of age-matched wild-type controls.  
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4.2. Ultrastructural analysis reveals both ageing and Cfh deletion affect the 
positioning of mitochondria and melanosomes in RPE 
A healthy functioning RPE is key in maintaining homeostasis across the retina, and age-
related changes are well documented in the RPE (see Sections 1.4.4.1-5). Cfh gene 
knock-out reversed some of these age-related ultrastructural changes and advanced 
others, when examined in 2 year old mice (Coffey et al., 2007). In order to allow 
detailed ultrastructural examination of the RPE, transmission electron micrographs 
were prepared from 7-8 week (Figure 4.2) and 1 year (Figure 4.3) Cfh-/- and wild-type 
mice. It was reported that in 2 year wild-type mice, electron-dense material 
accumulates in the basal region within the RPE and that this is decreased in Cfh-/- 
retinas (Coffey et al., 2007). In both young and 1 year old samples, electron 
micrographs showed clear basal infoldings with no sign of any accumulation of 
electron-dense material towards the basal surface. In both Cfh-/- and wild-type samples 
there was an expected increase in lipofuscin with age which is consistent with previous 
studies (Wing et al., 1978), although levels of lipofuscin did not appear significantly 
different between genotypes. Ageing was associated with a large proportion of 
photoreceptors dissociating from the apical processes of the RPE in both Cfh-/- and 
wild-type mice. However, we did not observe photoreceptors lying horizontally across 
the RPE as was observed in the 2 year Cfh-/- retinas (Coffey et al., 2007).  
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In the 2 year Cfh-/- animals it was reported that melanin and lipofuscin-containing 
organelles were more evenly distributed throughout the cell compared to age-
matched wild-type controls where they were predominantly apical. The previous study 
did not address the localisation of mitochondria. In light of this, we analysed the 
distribution of both mitochondria and melanosomes in the RPE of both young (7-8 
weeks) and aged (1 year) Cfh-/- and age-matched wild-type mice (Figure 4.4). The cross-
sectional depth of the RPE cells, measured from the basal lamina to the base of the 
apical processes, was not significantly different across the four groups with an average 
height of 5 m. Mitochondria are normally localised towards the basal side of RPE 
where there is a large energy demand (Gouras et al., 2010). The distribution of 
mitochondria was unaffected by the loss of CFH at 7-8 weeks (Figure 4.4A). However, 
ageing caused mitochondria in wild-type RPE to become less polarised and were on 
average further from the basal lamina which is consistent with published data 
(Mishima and Kondo, 1981).  In 1 year Cfh-/- samples we observed the opposite 
whereby mitochondria were found closer to the basal lamina.  
 
Melanosomes are typically polarised towards the apical surface of RPE. Their position 
is suited to the absorption of scattered light, and thus protection of free radical 
generation in the basally arranged mitochondria. In wild-type retinas, melanosomes 
were on average 2 m further from the basal lamina than mitochondria and their 
position were not altered with ageing (Figure 4.4B) However, in the RPE of young Cfh-/- 
mice, melanosomes were slightly more apical than in wild-type mice. In contrast, in 1 
year Cfh-/- retinas, the opposite effect was observed, in that melanosomes were less 
polarised and on average 1 m from mitochondria. These analyses show that in 1 year 
Cfh-/- samples the basal polarity of mitochondria was accentuated, whereas there was 
a loss of apical polarity of melanosomes.  
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4.3. Retinal function is impaired in 1 year Cfh-/- mice 
In order to assess whether the morphological changes described here had any 
functional significance we performed ERGs. ERGs measure the electrical response of 
the retina to flashes of light stimuli by placing a small electrode on the surface of the 
cornea. A normal ERG trace is composed of a negative a-wave followed by a positive b-
wave. The a-wave records largely the activity of the photoreceptors whereas the b-
wave is mainly due to depolarisation of intermediate neurons in response to 
photoreceptor stimulation. Dark-adapted 1 year Cfh-/- and age-matched wild-type mice 
were exposed to flashes of light of increasing intensity. Overlaid scotopic ERG traces 
from both Cfh-/- and wild-type mice showed clear a- and b- waves (Figure 4.5A-B). 
Retinal function was assessed between groups by comparing the amplitude and time 
to peak for each wave. The amplitudes of both the a- and b-waves were not 
significantly different in 1 year Cfh-/- mice compared to wild-type controls (Figure 4.5C-
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D), and were similar to values reported in other 1 year pigmented mice (Chang et al., 
2008).  However, the time to reach the peak of the a- and b-wave was modestly 
increased in the 1 year Cfh-/- mice compared to wild-type (Figure 4.5E-F). An ANOVA 
showed that this increase was significant for the a-wave (p = 0.004) but not for the b-
wave. An unpaired Student t-test for each light intensity revealed that half of the a-
wave measurements were significantly increased in Cfh-/- mice. The slower response of 
the b-wave was not statistically significant. Given that the a-wave was significantly 
slower, the fact that the time to reach the peak of the b-wave (which is measured from 
t0) was not significantly different, suggests that neuronal activity after the 
photoreceptor response was not affected by the loss of CFH.  
 
After recording scotopic ERGs, mice were light-adapted for photopic ERGs in order to 
assess their cone-mediated responses. In rodents, photopic ERG recordings are smaller 
than scotopic measurements because cones account for only 3% of photoreceptors 
(Carter-Dawson and LaVail, 1979). Overlaid photopic ERG traces from both Cfh-/- and 
wild-type mice showed small a-wave responses at higher light intensities but clear b-
wave responses at lower light intensities (Figure 4.6A-B). Measurements of the a- and 
b-wave amplitudes showed no significant difference between 1 year Cfh-/- and age-
matched wild-type controls (Figure 4.6C-D). There were also no significant differences 
in the time to peak for both the a- and b-wave responses (Figure 4.6E-F). These results 
suggest that cone-mediated vision is unaffected by the loss of CFH in mice at 1 year of 
age.  
 
VEPs were recorded simultaneously to confirm that neuronal stimulation in the eye 
elicited subsequent neuronal activity in the visual cortex. VEP recordings from both 
Cfh-/- and wild-mice showed a negative wave that followed the b-wave of the ERG, 
indicating normal neural transmission (data not shown). Comparing the amplitude and 
time to peak for the negative wave of Cfh-/- to wild-type mice did not show any 
significant differences.  
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4.4. Stress related responses in the retina of 1 year Cfh-/- mice 
In view of the previous results suggesting features of accelerated ageing in the absence 
of CFH, we examined whether there were other signs of retinal stress in 1 year Cfh-/- 
mice. In the 2 year Cfh-/- animals it was reported that in some photoreceptors, short-
wavelength cone opsin was redistributed into the apical compartment of the cell 
(Coffey et al., 2007). Mislocalisation of opsins can indicate RPE dysfunction and may 
precede photoreceptor degeneration (Zhang et al., 2011). However, 
immunohistochemical staining of Cfh-/- and wild-type retinas for short-wavelength 
cone opsin showed normal distribution localised to the outer segments in both young 
(7-8 weeks) and aged (1 year) mice (Figure 4.7).  
 
Another indicator of retinal stress is up-regulation of expression of glial fibrillary acidic 
protein (GFAP). GFAP, an intermediate filament protein, is expressed by astrocytes and 
the endfeet of Müller cells in the GCL. In retinas stressed by injury or disease 
pathologies, GFAP expression is up-regulated in what is termed reactive gliosis 
(Bringmann et al., 2006). GFAP expression in the wild-type and young Cfh-/- retinas was 
restricted to astroglia in the GCL (Figure 4.8A-C). However, in 1 year Cfh-/- mice the 
GFAP positive cell processes were more disorganised than the structures seen in the 
control retinas. Additionally these processes were seen extending towards the IPL 
(Figure 4.8D), indicating that astroglial activation is evident in 1 year Cfh-/- retinas. 
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4.5. Organisation of the retinal vasculature is unaffected by the loss of CFH 
Previous reports on 1 and 2 year Cfh-/- mice generated conflicting data on whether the 
retinal vasculature is affected by the loss of CFH. The retinal vasculature is organised 
into three plexuses, the inner, intermediate and deep (see Section 1.3.4). Previous 
research has suggested that the deep plexus of 1 year Cfh-/- mice is significantly 
withered and has a reduced density when imaged by fluorescein angiography (Lundh 
von et al., 2009). We examined the retinal vasculature by flatmounting whole retinas 
to allow analysis of each plexus by confocal microscopy. Flatmounts of young (7-8 
weeks) and 1 year Cfh-/- and age-matched wild-type retinas were stained for collagen 
IV in the basement membrane, C3 and mouse IgG within vessels.  In all retinas 
examined, the three plexuses could clearly be identified by collagen IV and IgG staining 
(Figures 4.9-10, data for intermediate and deep plexuses not shown) and no 
differences were observed between wild-type and Cfh-/- retinas. As expected, C3 was 
present in the blood vessels of all three plexuses in wild-type mice. However C3 
staining was weak in the deep and intermediate plexuses of the Cfh-/- retinas but was 
stronger in larger vessels in the inner plexus though still below the level seen in wild-
type retinas. This is consistent with previous reports showing that plasma in Cfh-/- mice 
is deficient for C3 because its breakdown is able to continue unhindered (Pickering et 
al., 2002). Electron micrographs did not reveal any major structural defects in the 
retinal vessels of Cfh-/- mice (data not shown). 
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4.6. Activated C3 breakdown products are increased in the retinal vasculature of 1 
year Cfh-/- mice 
Since there is a continual breakdown of C3 in the plasma of Cfh-/- mice, we investigated 
whether by-products of C3 breakdown were present in the retinas of young and 1 year 
Cfh-/- mice and compared this to age-matched wild-type controls. Lundh von et al., 
(2009) reported C3b deposition along endothelial surfaces of inner and deep retinal 
vessels of 1 year Cfh-/- mice which correlated with vascular constrictions. Flatmounted 
retinas were stained for C3b, iC3b and C3c. Breakdown products were faintly observed 
at a similar intensity in the vessels of the deep and intermediate plexuses for both Cfh-
/- and wild-type retinas in young and 1 year mice (data not shown). Brighter staining 
was detected in vessels of the inner plexus (Figure 4.11-12), with the most intense 
staining clearly associated with red blood cells in the larger vessels. C3b and iC3b-
coated red blood cells appeared brighter in Cfh-/- mice compared to wild-type mice 
demonstrating the increase in C3 breakdown in Cfh-/- mice. Red blood cells express 
CR1, a receptor for C3b and iC3b, and this allows the clearance of complement-coated 
immune complexes to the liver for degradation (Fearon, 1980). Staining of breakdown 
products in the smaller vessels of the inner plexus did not have the definitive shape of 
red blood cells nor did staining localise to the walls of the vessels but rather looked to 
be diffuse within vessels. 1 year Cfh-/- mice had an increase in C3 breakdown products 
which appeared diffuse within the smaller vessels of the inner plexus in comparison to 
1 year wild-type controls. No accumulation of C3 breakdown products was observed in 
the RPE or Bruch’s membrane region (data not shown).  
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4.7. Expression of regulatory complement components in the retina 
In view of the uncontrolled C3 breakdown in Cfh-/- mice, we explored whether there 
was activation of the complement pathway downstream of C3 in the retina. Neither C5 
nor MAC staining were identified above that of the non-specific antibody control in 
either Cfh-/- or wild-type retinas (data not shown).  
 
We speculated that the lack of downstream complement activation, when there is 
unregulated C3 breakdown, could be due to up-regulation of complement regulators 
that compensate for the loss of CFH. CRRY is a rodent-specific complement regulator 
which serves both the co-factor and decay-accelerating roles of CFH. 
Immunohistochemical staining of 1 year Cfh-/- and age-matched wild-type retinas 
showed increased expression of CRRY on the inner side of the OPL. In some retinas, the 
staining pattern appeared clustered around densely packed areas of ribbon synapses 
marked by bassoon (Figure 4.13).  
 
DAF, like CFH can accelerate the decay of C3 convertases. Staining of DAF in retinal 
sections revealed positive staining in the GCL in wild-type mice which was unaffected 
by age (Figure 4.14A-B). This expression pattern was unchanged in young Cfh-/- mice 
(Figure 4.14C). In 1 year Cfh-/- retina, DAF antibody stained projections extending from 
the GCL into the IPL (Figure 4.14D). Positive staining was also present amongst the 
nuclei of the INL and in the OPL but did not extend into the ONL. Due to their different 
shape, it is unlikely that the DAF positive processes are the same as those positive for 
GFAP. We also attempted to examine the expression pattern of MIRL, a complement 
regulator which inhibits the formation of MAC. Testing two antibodies we were unable 
to identify specific staining that was different from that of the non-specific antibody 
control (data not shown). 
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4.8. Discussion 
Ageing of the retina is a well characterised process in both the human and mouse. 
Ageing leads to structural and functional changes in all compartments of the retina 
including the neuroretina, RPE, Bruch’s membrane and ocular perfusion. In wild-type 
mice this study showed several features which were consistent with normal ageing 
such as accumulation of lipofuscin in the RPE, a decrease in photoreceptor density, a 
higher propensity for the photoreceptors to detach and loss of polarisation of the 
mitochondria. The majority of these features which occurred in the ageing of wild-type 
mice also occurred in Cfh-/- mice except the loss of polarisation of mitochondria. Here 
we showed that mitochondria became more polarised with ageing in Cfh-/- mice. We 
speculate that this may reflect a higher energy requirement of the RPE in aged Cfh-/- 
RPE compared to age-matched wild-type mice.  
 
Several features of ageing were not identified in this study, such as an accumulation of 
debris in the basal infoldings of the RPE or Bruch’s membrane. Since we studied ageing 
from 7-8 weeks to 1 year we would not expect all features of ageing to be present.  
 
Although analysing the effect of CFH deficiency at a young age was not the major focus 
of this study we revealed only two features of all those analysed which were different 
between young wild-type and Cfh-/- retinas. Firstly we showed that loss of CFH caused 
C3 depletion in the plasma of the retinal vessels. This is consistent with Pickering et al., 
(2002) who show that C3 is markedly reduced in serum of Cfh-/- mice. Secondly we 
showed that melanosomes were more polarised towards the apical membrane in 
young Cfh-/- mice compared to young wild-type mice. We speculate that this may be an 
early defensive mechanism utilised by the RPE in response to enhanced C3b 
breakdown products. Peculiarly this feature was reversed when we compared 1 year 
wild-type mice to 1 year Cfh-/- mice. Here we found that melanosomes were less 
polarised in 1 year Cfh-/- RPE which suggests mild RPE dysfunction. However, in order 
to draw any firm conclusions, these analyses should be repeated in several more mice.  
 
One of the aims of this study was to analyse whether any of the structural or 
functional defects found in 2 year Cfh-/- mice (Coffey et al., 2007) were present in 
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younger Cfh-/- mice. We have observed that as in 2 year Cfh-/- mice, photoreceptors in 
1 year Cfh-/- mice showed a greater tendency to detach from the apical processes of 
the RPE than age-matched wild-type controls. We took this analysis further by 
measuring the density of nuclei in the ONL, and showed that thinning of the 
photoreceptors was enhanced in 1 year Cfh-/- mice compared to age-matched wild-
type controls. This may be due to a combination of neuroretinal stress and RPE 
dysfunction. Unlike in the 2 year Cfh-/- mice, ERG results showed that in the in 1 year 
Cfh-/- mice there was not a significant difference in the amplitude of either the a- or b-
wave under scotopic conditions from age-matched wild-type controls. However we did 
see an increased time to peak of the scotopic a-wave in 1 year Cfh-/- mice compared to 
age-matched wild-type controls. This is perhaps an early indicator of the loss of visual 
function seen in older animals. Immunohistochemical analysis did not reveal any 
stress-related redistribution of opsins in the photoreceptors. However, we did find 
early signs of retinal stress in astroglia of 1 year Cfh-/- mice, characterised by GFAP 
staining. The shape and length of the GFAP positive cell processes suggested these 
cells were astrocytes rather than Müller cells. In order to confirm this, sections could 
be co-stained with a marker for astrocytes but not Müller cells and co-localisation 
quantified. In conclusion, we have shown early features of most of the structural and 
functional differences reported between 2 year Cfh-/- mice and age-matched wild-type 
controls. 
 
One study on 1 year Cfh-/- mice proposed a role for CFH in ocular perfusion (Lundh von 
et al., 2009). These investigators reported that the deep plexus of the retinal vessels is 
withered due to deposition of C3b along endothelial surfaces. However, in this study 
we observed that the retinal vasculature appeared normal in young and 1 year Cfh-/- 
mice and that there was no sign of C3b deposition on endothelial surfaces. The 
discrepancy between these reports may be due to fixation methods since unlike Lundh 
von et al.,(2009), we did not perfuse fix the retinas.  
 
The presence of both structural and functional changes, although mild in the 1 year 
Cfh-/- mice, indicated that the retina was responsive to the deficiency of CFH by the age 
of 1 year. This led us to investigate whether the retina was able to compensate for the 
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deficiency in CFH by up-regulating other complement regulators. Here we have shown 
that there was indeed a redistribution of complement regulators in the retinas of 1 
year Cfh-/- mice. The enhancement of complement regulation in the neuroretina 
suggests that this area is particularly vulnerable to complement activation, in light of 
which, it would be interesting to analyse the expression of CRRY and DAF in 2 year Cfh-
/- mice. 
 
Age-related ocular pathologies are often due to an added stress such as a genetic or 
environmental factor which makes the retina unable to cope with the normal ageing 
process. Here we show that many of the more severe structural and functional 
changes identified in 2 year Cfh-/- mice are not present in 1 year Cfh-/- mice. This 
highlights the importance of ageing in the pathology of 2 year Cfh-/- mice.  
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Chapter 5: Results 
Microarray Analysis of RPE/Choroid and Neuroretina of Cfh-/- Mice 
It is evident that ageing is a key contributor to the retinal phenotype in the 2 year old 
Cfh-/- mice since not all the functional and morphological changes were present in 1 
year old Cfh-/- mice.  With the aim of understanding the mechanisms involved in this 
process we used a genome-wide microarray in order to analyse the gene expression 
profile of both the RPE and neuroretina of Cfh-/- mice at 7-8 weeks and 16 months of 
age. This allowed us to analyse the effect of both Cfh genotype and ageing on the 
retinal gene expression. This analysis required processing two tissues (RPE/choroid and 
neuroretina) from six mice in each of the four groups (Figure 5.1). This work was 
carried out in collaboration with Dr. Carsten Faber (University of Copenhagen). 
 
 
 
5.1. Isolation of RNA from RPE and neuroretina 
Isolation of neuroretina was achieved by dissecting the posterior eyecup and peeling 
out the neuroretina. Isolation of RNA from the neuroretina gave a good yield of RNA, 
ranging from 3.8-6.4 g RNA per pair of eyes. Since the RPE is a monolayer, isolation of 
sufficient RNA for microarray analysis required initial optimisation. First, separation of 
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the RPE from the choroid was attempted by incubation of posterior eyecups in trypsin 
or dispase. The yield of RNA using this method was low and to be suitable in this study 
would have required pooling multiple eyes from several mice. Moreover, RT qPCR 
analysis of the RNA isolated revealed endothelial-specific Pecam1 gene expression, 
showing that there was vessel contamination from the choroid (data not shown). 
Nevertheless, isolation of both the RPE and choroid allowed recovery of a larger 
proportion of the total RPE cells, so isolation of RPE/choroid by incubation with TRIzol® 
or manual scraping of the pigmented cells was compared. After isolation of RNA, 
proteins were extracted from the same preparation and resolved by SDS-PAGE. 
Western blotting for RPE65 showed that manual scraping of the pigmented cells from 
the posterior eyecup achieved a higher proportion of the RPE-specific protein 
compared to incubation of the posterior eyecup in TRIzol® (Figure 5.2). Manual 
scraping produced yields of 0.5-1.2 g RNA per pair of eyes. 
 
 
 
5.2. RNA quality assessment prior to microarray analysis 
Microarray analysis requires RNA of a high integrity. Here, RNA quality was assessed 
using a bioanalyzer where a fluorescent dye intercalates with nucleic acids which are 
subsequently separated by electrophoresis (Figure 5.3A). Analysis of the 18S and 28S 
ribosomal RNA (rRNA) peaks on the electrophoresis traces gives an indication of any 
RNA degradation (Figure 5.3B). The traces also indicate the presence of any DNA or 
phenol contamination. The bioanalyzer software generates a RNA integrity number 
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(RIN) by applying an algorithm to the entire electrophoresis trace. This number ranges 
from 1-10, with 10 representing the maximum integrity value. Using the highest RIN 
scores, four of the six RNA samples collected were chosen for microarray analysis. The 
average RIN score for RPE/choroid RNA was less than that of neuroretina RNA which is 
likely due to low yield of RPE/choroid RNA compared to the neuroretina (Figure 5.3C).   
 
 
 
 
5.3. Microarray analysis 
RNA was processed at the UCL genomics facility and underwent a sense target labelling 
assay to generate amplified biotinylated sense-strand DNA. Due to the low 
concentration of RPE/choroid RNA, the RNA was linearly amplified prior to the 
labelling assay. Each sample was hybridised to an Affymetrix Mouse Gene 1.0 ST Array 
GeneChip® then stained and scanned. Each chip contained approximately 27 probes 
for every known gene and Ensembl predicted EnsGene, equating to 28,853 genes 
across the mouse genome. 
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UCL Genomics carried out statistical analysis of the microarray raw data using Partek® 
software. Using this software, data underwent background adjustment and 
normalisation to account for variance in labelling and hybridisation between chips. 
Differential expression between groups was analysed by ANOVA whilst controlling for 
false discovery rate.  
 
PCA was applied to all genes to assess variance within and between groups. PCA of the 
RPE/choroid samples showed that samples within the young wild-type group had the 
most variance whereas the four samples in the other three groups largely clustered 
together (Figure 5.4A). PCA analysis of the neuroretina samples showed that the young 
groups had less variance between samples than the aged groups (Figure 5.4B). Overall, 
the neuroretina groups were more variable than the RPE/choroid groups, which may 
be due to the multicellular nature of the neuroretina in comparison to the 
RPE/choroid. One outlier in the young Cfh-/- neuroretina group was removed from 
analyses because it was vastly different to the other three samples of its group. Overall 
variance between samples of each group was expected since RNA was not pooled from 
multiple mice but each sample represented RNA from one mouse. Additionally, 
comparisons between varied groups should give more confidence in the genes which 
are shown to be significantly different between them.  
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Statistical analysis of the microarray data was performed to compare the effect of 
either Cfh genotype or age between groups. These comparisons identified which genes 
were significantly changed in either the RPE/choroid or the neuroretina as a result of 
the loss of CFH or ageing. Analysis of the RPE/choroid showed that in both wild-type 
and Cfh-/- mice, approximately 450-550 genes exhibited changes in expression as a 
function of ageing that met the criteria for significance (Figure 5.5A). In contrast, age-
related gene expression was more stable in the neuroretina, though as with 
RPE/choroid, somewhat fewer changes in gene expression were observed in the Cfh-/- 
mice (Figure 5.5B). Interestingly, despite the large number of age-related changes in 
gene expression in the RPE/choroid, only a few differences were noted between wild-
type and Cfh-/- mice, namely 5 in the young and 21 in the aged animals. However, in 
the neuroretina there were 12 significant differences between the young wild-type 
and Cfh-/- animals and >100 between the aged counterparts. Thus, deletion of Cfh 
appears to have a greater impact on the transcriptomics of ageing in the neuroretina 
than the RPE/choroid. This may appear counter-intuitive in light of the fact that CFH 
expression in the retina is predominantly in the RPE but is consistent with the 
observed changes in visual function in the aged Cfh-/- mice (Coffey et al., 2007). 
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5.4. The effect of Cfh genotype on gene expression in the RPE/choroid 
In young animals, as expected, Cfh was the most down-regulated gene in Cfh-/- mice. In 
addition to Cfh, only four other genes were significantly altered compared to age-
matched wild-type controls (Table 5.1). These four genes were all down-regulated in 
Cfh-/- mice but their functions could not be linked to a single pathway. Of the four 
genes, both diazepam binding inhibitor (Dbi) and minichromosome maintenance 
deficient 6 (Mcm6) remained significantly altered when comparing aged Cfh-/- 
RPE/choroid to age-matched wild-type controls. 
 
 
 
The loss of CFH had a greater impact on the RPE/choroidal gene expression of aged 
mice than that of younger mice (Table 5.2). In addition to Cfh, 20 genes were 
differentially expressed between aged Cfh-/- mice and age-matched wild-type controls. 
Ingenuity Pathway Analysis® did not reveal a direct or known functional link between 
any of these 20 genes. 
 
Pituitary tumour-transforming gene 1 (Pttg1) was the most up-regulated gene in the 
RPE/choroid of aged Cfh-/- mice compared to age-matched wild-type controls with over 
a six fold change. However Pttg1 expression was also down-regulated with age in wild-
type mice therefore the apparent up-regulation in aged Cfh-/- mice may actually be the 
consequence of the gene not being down-regulated with ageing in these mice. Pttg1 is 
a proto-oncogene involved in sister chromatid segregation important for mitotic 
checkpoints and cell proliferation (Pei and Melmed, 1997). Pttg1 has also been shown 
to be involved in regulation of transcription, apoptosis and endothelial cell survival 
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(Bernal et al., 2002), and dysregulation of this gene has been identified in mouse 
models of photoreceptor degeneration and retinal dystrophy (van de Pavert et al., 
2007; Fernandez-Medarde et al., 2009; Yetemian et al., 2010). However 
characterisation of the Pttg1-/- mouse reported no morphological or functional 
changes in the retina, suggesting that Pttg1 dysregulation is a secondary event to 
perhaps cell stress or neovascularisation (Yetemian and Craft, 2011). The significance 
of Pttg1 expression in relation to Cfh gene knock-out is not clear. 
 
 
 
Cathepsin E (Ctse) gene expression was over three fold higher in RPE/choroid in aged 
Cfh-/- samples compared to age-matched wild-type controls, but its expression did not 
significantly change with ageing in either Cfh-/- or wild-type mice. However cathepsins 
B, H, K and S were all up-regulated with age in both Cfh-/- and wild-type mice. CTSE is 
an intracellular non-lysosomal aspartic proteinase, and has been reported to 
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accumulate in neural tissue with ageing and neurodegeneration, and co-localises with 
lipofuscin. One retinal study reported CTSE expression in the neurons of the inner, OPL 
and GCL (Bernstein et al., 1998). However, attempts to validate this up-regulation by 
western blot analysis of RPE/choroid lysates from aged Cfh-/- mice were thwarted 
because protein expression was below the detectable limit of the assay (data not 
shown). 
 
At 16 months, synuclein alpha (Snca) gene expression was even more down-regulated 
than that of Cfh. This gene was up-regulated with age in wild-type mice, therefore the 
down-regulation in aged Cfh-/- mice can also be interpreted as a failure to up-regulate 
the gene with ageing in the Cfh-/- mice. SNCA is primarily expressed by neurons; in the 
eye it is expressed by RPE, photoreceptors, amacrine and bipolar cells (Martinez-
Navarrete et al., 2007). The protein is thought to be involved in neuronal transmission 
and maintenance of the outer segment of the photoreceptors but its function in RPE is 
unknown. 
 
Retinol binding protein 7 (Rbp7) was the most down-regulated gene after Scna and 
Cfh. However like Scna, Rbp7 expression was also found to be up-regulated with age in 
wild-type mice. RBP7 is the most recently identified cellular retinol binding protein and 
is therefore not yet well characterised (Vogel et al., 2001). RT qPCR analysis of cDNA 
reverse transcribed from the RNA used for microarray analysis confirmed a down-
regulation of Rbp7 transcript levels in aged Cfh-/- RPE/choroid (Figure 5.6). 
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5.5. The effect of Cfh genotype on gene expression in the neuroretina 
The loss of CFH significantly altered the expression of 11 genes in the neuroretina of 
young mice (Table 5.3). None of the genes that were significantly altered at a young 
age in RPE/choroid were also altered in the neuroretina which indicated that there 
was no significant contamination of the neuroretina tissue in the RPE/choroid 
isolation and vice versa. Of the 11 genes, 10 were down-regulated in aged Cfh-/- 
compared to wild-type age-matched controls. All of these 10 genes, like Cfh, are 
located on mouse chromosome 1, which suggests that targeting of the Cfh gene may 
affect expression of neighbouring genes. 
 
Zinc finger RAN binding domain containing 3 (Zranb3) was up-regulated 10.9 fold in 
young Cfh-/- neuroretina.  Zranb3 is a member of the SNF2/RAD54 helicase family, its 
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biological function is not defined but it has been suggested to be involved in G-
protein function (Chen et al., 2011). 
 
 
 
In contrast to previous comparisons, the aged neuroretina was markedly affected by 
the loss of Cfh, with 110 genes being significantly different between aged Cfh-/- and 
age-matched wild-type controls (Table 5.4). Of these, 24 were located on mouse 
chromosome 1, of which 19 were down-regulated in Cfh-/- neuroretina. 
 
SLU7 splicing factor homolog (Slu7) involved in pre-mRNA splicing exhibited the 
highest fold change, with 36.57 fold up-regulation in Cfh-/- neuroretina. Human Slu7 
is highly expressed in the GCL and INL (Alberstein et al., 2007). 
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Three complement genes were down-regulated in the neuroretina of aged Cfh-/- 
mice compared to age-matched wild-type controls. Two of these, Cfhr2 and Cfhr3 
are both located close to the Cfh locus on mouse chromosome 1 (Figure 5.12). With 
the large number of differentially expressed genes on chromosome 1 it is difficult to 
judge whether the down-regulation of Cfhr2 and Cfhr3 is an off-target consequence 
of Cfh gene disruption, or a functional response to the loss of CFH protein. The third 
gene, Cd59a, exhibited a small down-regulation of 1.5 fold. CD59a is a regulator of 
MAC formation also known as MIRL. As with Rbp7, Cd59a expression was up-
regulated 1.6 fold in the wild-type neuroretina by ageing, so again, the down-
regulation in aged Cfh-/- mice could also be interpreted as a lack of up-regulation 
with ageing of Cfh-/- mice.   
 
Four of the genes not on chromosome one, Pttg1, dynein light chain Tctex-type 1 
(Dynlt1) and two RIKEN cDNA sequences were up-regulated in the Cfh-/- mice in both 
aged RPE/choroid as well as the neuroretina. The two Riken cDNAs have yet to be 
characterised. Pttg1 was up-regulated 22.6 fold in comparison to age-matched wild-
type controls. As in the RPE/choroid, Pttg1 was also down-regulated with age in the 
neuroretina of wild-type with a fold change of -46. Therefore, like in the 
RPE/choroid, the 22.6 up-regulation measured in aged neuroretina of Cfh-/- mice 
could be interpreted as the absence of down-regulation with age. DYNLT1 forms 
part of the dynein 1 complex which acts a motor for organelle and vesicle transport 
along microtubules (King et al., 1996; Nagano et al., 1998). Dynein is involved in the 
transport of rhodopsin vesicles along microtubules and it is DYNLT1 which binds the 
dynein complex to rhodopsin in photoreceptors (Tai et al., 1999). Mutations 
associated with retinitis pigmentosa have been shown to affect the binding of 
DYNLT1 to rhodopsin. 
 
Ingenuity Pathway Analysis® of the 110 genes revealed the top ten canonical 
pathways and cellular functions affected in the aged neuroretina of Cfh-/- mice 
(Figure 5.7). The majority of the canonical pathways affected are involved in the 
metabolism of amino acids or cell signalling. This analysis also showed that cell-to-
cell signalling is affected which is relevant to a healthy functioning retina.  From this 
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pathway, 4 genes from the list of 110 are represented including AFG3 (ATPase family 
gene 3)-like 2 (Afg3l2), calcium channel, voltage-dependent, L type, alpha 1S subunit 
(Cacna1s), cadherin 2 (Cdh2) and integrin alpha V (Itgav). 
 
5.6. The effect of ageing on the RPE/choroid  
Although ageing affected the expression of a similar number of genes in the 
RPE/choroid of wild-type (527) and Cfh-/- (454) mice, only 192 of these genes were 
the same genes. This suggests that the ageing process of the RPE/choroid in Cfh-/- 
mice is different to that of wild-type mice. Interestingly, Ingenuity pathway analysis® 
revealed that the majority of the canonical pathways (Figure 5.8) and cellular 
functions (Figure 5.9) which were affected, principally involved the immune system 
in both wild-type and Cfh-/- mice. This is consistent with previous literature reporting 
that RPE/choroid of wild-type mice becomes immunologically active with age (Chen 
et al., 2008).  
 
 5.7. The effect of ageing on the neuroretina 
There were fewer gene expression changes associated with ageing of the neuroretina 
than in the RPE/choroid, suggesting that this tissue is less susceptible to the effects of 
ageing. But in contrast to the RPE/choroid, there was a large difference in the number 
of genes which were found to be significantly different in the ageing neuroretinas of 
wild-type compared to Cfh-/- mice. 109 genes were differentially expressed during 
ageing of the wild-type neuroretina, compared to only 29 in the ageing Cfh-/- 
neuroretina. Of these, 14 genes were found in both groups. Ingenuity pathway 
analysis® revealed which were the top ten canonical pathways (Figure 5.10) and 
cellular functions (Figure 5.11) affected. None of the top ten canonical pathways 
affected by ageing were common to both wild-type and Cfh-/- mice, consistent with the 
notion that gene expression in the ageing of the neuroretina is modified in Cfh-/- mice.  
  
 
135 
 
  
 
136 
 
  
 
137 
 
  
 
138 
 
 
  
 
139 
 
5.8. The effect of ageing on the complement system 
Surprisingly no genes directly involved in the complement system were affected by the 
loss of CFH in RPE/choroid and very few in the neuroretina. However the complement 
system was the main canonical pathway affected by ageing in the RPE/choroid of both 
wild-type and Cfh-/- mice (Figure 5.8). The majority of these age-related changes were 
similar in both wild-type and Cfh-/- mice (Table 5.5). Complement expression in the 
neuroretina was largely unaffected by age (Table 5.6).  
 
Cfh expression was not significantly affected by age in either the RPE/choroid or the 
neuroretina of wild-type mice, consistent with a previous report in humans where CFH 
mRNA was shown not to change with age (Hageman et al., 2005). 
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5.9. Discussion 
This study highlights how ageing has a dramatic effect on the gene expression profile 
of both the RPE/choroid and the neuroretina. Ageing was associated with more genes 
being differentially expressed in wild-type retina compared to Cfh-/- mice. 
Nevertheless, ageing has a significant impact on gene expression in the Cfh-/- mice, 
since there were very few differences in gene expression in either the RPE/choroid or 
neuroretina of young Cfh-/- mice when compared with controls. Indeed, all bar three of 
the genes that were differentially expressed in young Cfh-/- mice in both RPE/choroid 
and the neuroretina were located near the Cfh locus on chromosome 1. The number of 
genes on mouse chromosome 1 which were differentially expressed in Cfh-/- mice 
increased with age. The positions of most of these genes were centromeric to the Cfh 
locus, and those with the highest fold changes were located closest to the Cfh locus 
(Figure 5.12). The majority of these genes were down-regulated in the Cfh-/- mice. It is 
possible from these results that the neomycin selectable cassette inserted into the Cfh 
gene exerts non-specific positional effects on the expression of neighbouring genes. 
Although the mechanism is not known for how this may occur, several studies have 
shown effects of selectable marker cassettes on neighbouring genes (Rijli et al., 1994; 
Meier et al., 2010).  Nevertheless, it is possible that some of the genes which were 
differentially expressed on chromosome 1 are a genuine downstream effect from the 
loss of CFH. 
 
The functions of the genes differentially regulated on chromosome 1 are diverse 
including, neural transmission, DNA replication, transcription, cytoskeleton, vesicular 
transport, cellular junctions, cell signalling and the immune response. This discovery 
must be considered when interpreting changes in gene expression from genes on 
other chromosomes and the overall effects on phenotype.  
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It was surprising to see that Snca was down-regulated more than Cfh, the original 
gene disrupted. Since this gene is not located on chromosome 1 it is unlikely that the 
down-regulation was due to the neo cassette insertion. The role of synuclein alpha 
outside of neurons is not known. One possible cause of the large down-regulation is 
that the original mouse strain used to make the knock-out had a disruption in this 
gene. The mouse strain used had a 129/Sv x C57Bl/6 hybrid genetic background. It is 
known that C57Bl/6J mice from Harlan contain a chromosomal deletion at the Scna 
locus (Specht and Schoepfer, 2001). In order to clarify if the down-regulation 
measured in the microarray was genuine, Cfh-/- mice would need to be genotyped in 
the region of the reported deletion (Specht and Schoepfer, 2004). 
  
 
144 
 
Chapter 6: Discussion 
The complement system is currently emerging as a key feature of several eye diseases. 
CFH was the first member of the complement system identified as playing a role in the 
pathogenesis of AMD after the landmark discovery of a SNP present in over 50% of 
patients (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 
2005). Prior to 2005, little was known about the role of CFH in the healthy retina. This 
study reports an investigation into the role of CFH in the retina in order to clarify its 
significance in AMD pathogenesis. 
 
This work was carried out using two experimental systems; in vitro through the use of 
RPE cells in culture and in vivo with the use of a knock-out mouse. In vitro experiments 
were informative for understanding the secretory pattern of CFH from RPE cells. Using 
the RPE cell line, ARPE19, we show that, as in primary porcine RPE, CFH is secreted 
upon serum removal via de novo synthesis. The secretory pattern suggests that CFH is 
secreted constitutively but only at a low level. However, CFH secretion could be 
enhanced by the presence of pro-inflammatory cytokines IFN  or IL-1β. In contrast our 
in vivo model allowed us to investigate the retina as a tissue and using this approach 
we analysed how the loss of CFH affected the health of the retina when mice were 
young and at 1 year. Loss of CFH had little effect on the health of the retina at 7-8 
weeks with only a mild redistribution of melanosomes in the RPE. Indeed, an analysis 
of gene expression, revealed only 5 and 12 genes were significantly affected by the loss 
of CFH in the RPE and neuroretina respectively. At 1 year of age however, the loss of 
CFH had a greater impact where we were able to identify structural and functional 
changes and an increased number of genes had altered expression with 21 and 110 
genes identified as significantly altered in the RPE and neuroretina respectively. Loss of 
CFH led to changes observed in the RPE, where organisation of mitochondria and 
melanosomes were disrupted and in the neuroretina where there was thinning of 
photoreceptors, re-distribution of complement regulators and early signs of reactive 
gliosis. Functional tests revealed that the loss of CFH did not impact upon the 
amplitude of the neural responses but did delay the response of the rod 
photoreceptors indicating a significant role for CFH in aged mice. 
 
  
 
145 
 
An increased role for CFH with age in the eye fits with the notion that dysfunction of 
this protein manifests in the age-related eye disease, AMD. In order to understand 
how regulation of the alternative complement pathway is important to retinal 
structure and function we chose to use Cfh-/- mice to characterise the role of this 
protein in the retina at a young and intermediate age. For AMD research the use of 
mouse models seems counter-intuitive since mice do not have a macula, and therefore 
generation of a mouse which recapitulates all the features of AMD would be 
challenging. Instead, mouse models are suitable for investigating components of this 
multifactorial disease.   
 
Immunohistochemical analysis of retinas revealed that due to the loss of CFH several 
changes were present in the inner retina where we observed altered expression of 
both GFAP and DAF in 1 year mice. GFAP positive processes extended from the GCL 
into the IPL in 1 year Cfh-/- mice, which we believe to be astrocytic processes indicative 
of reactive gliosis. Reactive gliosis is one of the first signs that occur when the retina is 
undergoing stress brought about by injury or disease. In AMD, up-regulation of GFAP in 
the inner retina is associated with the presence of drusen whereas up-regulation in the 
outer retina is associated with BRB disruption (Vogt et al., 2006). Within the inner 
retina lie the three plexuses of the retinal vasculature. Our results indicate that C3b is 
present in large quantities in these vessels as compared to wild-type mice. We were 
not able to identify any build up of C3b or C3 on vessel walls as observed by Lundh von 
et al., (2009) however this may be due to different fixation methods used. One could 
hypothesise that constant exposure to the enhanced C3b in the retinal vasculature 
may bring about subtle changes to those vessels or to the perivascular cells, which 
astroglial cells are capable of detecting. Indeed, Lundh von et al., (2009) reported that 
in 1 year Cfh-/- mice the enhanced deposition of C3 and C3b in the inner vasculature of 
the retina was associated with withering and reduced perfusion. A reduced rate of 
perfusion could be one of the causes of retinal stress of the astroglial cells in the inner 
retina of 1 year Cfh-/- mice since GFAP is known to be upregulated in other traditional 
models of ischaemia such as oxygen-induced retinopathy (DeNiro et al., 2011). 
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Within the same region of the retina as GFAP, we also observed up-regulation of the 
complement regulator DAF however their staining patterns were different suggesting 
that DAF was up-regulated in a different cell type in the inner retina. The DAF positive 
processes stretching from the GCL to the OPL are characteristic of the shape of Müller 
cells however this should be confirmed by co-staining for a Müller cell specific marker. 
This up-regulation shows the ability of the retina to compensate for the loss of CFH by 
up-regulating a protein which serves several of the same functions of CFH. In human 
retina, DAF is localised to the ganglion cell layer (Fett et al., 2012) and has recently 
been shown to be up-regulated in the region of the OLM in patients with AMD (Vogt et 
al., 2006). Our results suggest that the up-regulation of DAF observed in patients with 
AMD is directly due to the loss in expression or function of CFH. 
 
Another complement regulator, CD59a, was identified by microarray analysis as being 
down-regulated (see Chapter 5) in the neuroretina of 1 year Cfh-/- mice. In humans, 
CD59, like DAF, is expressed in the GCL (Sohn et al., 2000) but unlike CRRY and DAF, 
CD59a inhibits the assembly and function of MAC in the terminal complement 
pathway. We were unable to verify the presence of MAC formation in the neuroretina 
of wild-type or Cfh-/- mice by immunohistochemistry with the use of several antibodies. 
MAC has been shown to be constantly active at a low level in the iris, ciliary body, 
corneal epithelium, sclera and choroid of adult rats (Sohn et al., 2000), however the 
presence of MAC in the normal mouse retina has not been described in the literature. 
In AMD, MAC is detected on the RPE, choroidal blood vessels and drusen (Bora et al., 
2006). MAC generation is believed to be an important mediator of CNV in laser-
induced mouse models since blocking MAC generation using C5-/- mice or by up-
regulating CD59a significantly reduced development of CNV lesions (Bora et al., 2006; 
Bora et al., 2007). The generation of MAC via activation of the alternative pathway is 
important for CNV development since CNV is inhibited in Cfb-/- but not C4-/- mice 
(Brooimans et al., 1989). Given this, one would expect CNV lesions to be exacerbated 
in Cfh-/- mice due to a less controlled regulation of the alternative pathway. However 
Lundh von et al., (2009) report that laser-induced CNV is less severe in Cfh-/- mice 
compared to wild-type mice which they believe is due to lower perfusion rates in the 
choriocapillaris. Although we were unable to verify whether there was low level MAC 
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generation present in 1 year wild-type, it may be that up-regulation of DAF and CRRY 
protein expression in 1 year Cfh-/- mice enabled better control of terminal pathway 
activation and redundancy of CD59a function leading to its down-regulation in Cfh-/- 
mice. Better control of the terminal pathway in 1 year Cfh-/- mice may be a reason for 
the reduced lesion size observed by Lundh von et al., in their laser induced CNV 
experiments. Alternatively, the down-regulation of CD59a seen in 1 year Cfh-/- mice 
may lead to deposition of MAC but at levels below the limit of detection by 
immunohistochemistry. Uncontrolled MAC generation can cause harmful bystander 
damage to healthy tissue and may have contributed to the mild degeneration seen at 1 
year in Cfh-/- mice where there was thinning in the photoreceptors, ONL and INL. MAC 
can also have sub-lytic effects where in RPE it has been shown to stimulate the 
secretion of IL-6, IL-8, MCP-1 and VEGF (Lueck et al., 2011). Gene expression analysis 
did not reveal a significant increase in the expression of these molecules suggesting 
that either MAC formation did not occur in Cfh-/- mice or that it was formed elsewhere 
in the retina.  In future experiments it will be important to validate CD59a protein 
expression by immunohistochemistry or immunoblot and to analyse MAC expression 
by immunoblot in the retina of Cfh-/- mice.  
 
In contrast to the inner retina where we observed differences in GFAP and DAF 
expression but the overall morphology was normal, in the outer neuroretina we 
observed altered morphology with thinning of the photoreceptors and reduced nuclei 
density in the ONL in 1 year Cfh-/- mice. Close to this region we also observed up-
regulation of the complement regulator CRRY clustered around the ribbon synapses of 
the OPL, demonstrating that this area is responsive to changes in the complement 
system. We are uncertain as to the direct cause of the cell death observed in the 
photoreceptors of 1 year Cfh-/- mice however some clues can be taken from gene 
expression analysis of the neuroretina. There were 109 genes which were significantly 
differentially expressed in 1 year Cfh-/- mice as compared to age-matched wild-type 
controls. Of these 109 genes, Pttg1 is of particular interest since it is dysregulated in 
other models of photoreceptor degeneration (van de Pavert et al., 2007; Fernandez-
Medarde et al., 2009; Yetemian et al., 2010). Pathway analysis identified amino acid 
metabolism and signalling between cells to be the main pathways affected by the loss 
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of CFH in the neuroretina at 1 year. These two functions are integral to the normal 
functioning of the neuroretina. We speculate that photoreceptor cell death may be the 
result of reduced interaction of the photoreceptors with neighbouring cells such as the 
RPE. Indeed we observed a greater tendency for the photoreceptors to detach from 
the RPE in 1 year Cfh-/- mice when preparing fixed sections for electron microscopy and 
immunohistochemistry. The death of photoreceptors in 1 year Cfh-/- mice had an 
impact on visual function since we recorded a decreased time to peak of the a-wave 
when stimulating the rod photoreceptors under scotopic conditions. 
 
The phenotype characterised in these mice at 1 year is mild, with subtle differences 
revealed by ERG in the scotopic a-wave, RPE organelle distribution, ONL density and 
GFAP expression. The ability of the retina to cope with the loss of CFH may be due to 
the up-regulation we observed of membrane-bound complement regulators, CRRY in 
the OPL, and DAF in the GCL, IPL, INL and OPL. Our results highlight the ability of the 
neuroretina to adapt its expression of complement regulators in response to loss of 
CFH. Surprisingly this up-regulation, observed by immunohistochemistry, was not 
observed upon gene expression analysis of the neuroretina of 1 year Cfh-/- mice. This 
suggests that the up-regulation of these proteins was due to an effect occurring post-
translation, emphasising the importance of not assuming that mRNA expression is 
equivalent to protein expression. Alternatively it could suggest that up-regulation of 
DAF or CRRY was in a small subset of cells which did not reach statistical significance 
over the background of the other cells present in the neuroretina. However, we should 
also consider, that these two analyses were carried out using mice of slightly different 
ages (1 year and 1 year 4 months), therefore it is possible (albeit unlikely), that protein 
expression although enhanced at 1 year in Cfh-/- mice, returned to that of age-matched 
wild-type controls by 1 year 4 months, or that age-matched wild-type controls also up-
regulated these genes within the 4 months these analyses were carried out. 
 
Gene expression analysis did reveal that in 1 year Cfh-/- mice, more genes in the 
neuroretina were differentially regulated as compared to the RPE/choroid. This 
suggests that the absence of CFH has a larger impact on the neuroretina than the 
RPE/choroid. Similarly, the majority of the differences between 1 year Cfh-/- and age-
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matched wild-type controls identified in Chapter 4 were in the neuroretina. These 
results draw attention away from the RPE, dysfunction of which is central to AMD, to 
focus instead on the neuroretina. Conversely an analysis of ageing of both the wild-
type and Cfh-/- mice revealed significantly more genes were differentially regulated in 
the RPE/choroid as compared to the neuroretina. We speculate that the ability of the 
RPE/choroid to adapt gene expression to a larger extent with age may render these 
tissues more protection against the damaging effects of ageing. Interestingly the main 
cellular and canonical pathways affected by ageing in the RPE/choroid of both 
genotypes were the complement system, acute phase response signalling and 
inflammatory responses highlighting how the innate immune system is the most 
significantly affected pathway by ageing in this tissue. 
 
Although the use of Cfh-/- mice was informative in understanding the role of CFH in the 
retina we also wanted to investigate the expression pattern of CFH by RPE which is 
believed to be the main source of CFH in the eye. Our results corroborate this belief 
since gene expression analysis of wild-type mice showed that Cfh gene expression was 
higher in RPE/choroid as compared to the neuroretina. To investigate CFH secretion 
we used an in vitro approach and developed a secretory assay using ARPE19 cells, 
where spent media was precipitated with TCA and proteins were subsequently 
resolved by SDS PAGE and western blotted for CFH.  This approach allowed us to test 
whether external stimuli could modulate CFH secretion. For quantitative analysis, 
samples were spiked with goat IgG to act as a loading control. In hindsight, the 
development of an enzyme-linked immunosorbent assay would have had several 
advantages including more sensitive detection of CFH, increased accuracy and being a 
faster technique.  
 
Since different tissues express different members of the complement system at 
various levels, some of which are constitutively expressed and some factors that are 
only expressed in response to inflammation, we used our in vitro assay to determine 
secretion patterns from RPE. We have confirmed that RPE cells in culture secrete CFH 
de novo consistent with human umbilical vein endothelial cells (Penfold et al., 2001), 
and provide evidence that this secretion is constitutive. Constitutive expression of CFH 
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by ARPE19 cells has previously been disputed by Wu et al., (2007) who reported that 
IFN  stimulation is required for CFH expression from ARPE19 cells. This discrepancy in 
results is most likely because we were able to detect a lower level of expression by 
concentrating spent media with TCA. Our results are in agreement with data from 
primary human RPE where CFH is shown to be secreted in a constitutive manner (Kim 
et al., 2009). Constitutive secretion of CFH from RPE suggests that there is a constant 
requirement for complement regulation in the retina which is not met by a systemic 
contribution. However because the concentration of secreted CFH was not high 
enough to be detected by western blotting without prior concentration this suggests 
that constitutive secretion, at least by ARPE19 cells in culture, is only at a low level. It is 
possible therefore that complement regulation in the retina is supplemented by 
systemic CFH from the choroid.  This would imply that gene or stem cell therapy to 
correct a SNP in CFH in RPE may not be a successful approach for treating AMD. 
 
Several pathological mechanisms involved in AMD can influence the behaviour of RPE 
cells including oxidative stress, lipid metabolism and inflammation. We chose to 
investigate the effect of inflammation on CFH secretion in our secretion assay since 
complement expression is known to be modified by this process in several cell types. 
As in other cell types, we showed that RPE cells in culture enhance secretion of CFH in 
response to IFN . Kim et al., (2009) have previously shown this using cultured human 
foetal RPE however this is the first report showing that CFH secretion from ARPE19 
cells is similar to primary human RPE cells. Additionally, we showed for the first time in 
this cell type that another pro-inflammatory cytokine, IL-1 , also enhanced CFH 
secretion from RPE cells in culture.  In AMD, the RPE is exposed to  cytokines from 
several sources, including activated microglial cells which migrate towards the sub-RPE 
space with age (Tsutsumi et al., 2003), macrophage infiltration during CNV (Yu et al., 
2007) and from the RPE cells themselves in an autocrine or paracrine manner. Our 
experiments however, reflect the response of healthy RPE cells to pro-inflammatory 
cytokines. In AMD, where RPE cells are exposed to several stresses such as oxidative 
stress (see Section 1.4.4.1) and altered lipid metabolism (see Section 1.4.4.2) the RPE 
may have an altered response to pro-inflammatory cytokines where perhaps an 
enhanced CFH secretion is not able to be maintained allowing complement activation 
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to ensue. Evidence for this comes from the data collected from our serial samples 
where the RPE cells were exposed to the stress of the media being changed every two 
hours. In this case we observed a drop in CFH secretion over time, suggesting that cell 
stress may diminish CFH secretion. 
 
At present it is not known whether CFH secreted by RPE cells is functionally active. In 
order to test this, CFH collected from RPE cells in culture could be used in a haemolytic 
assay where sheep red blood cells are incubated with CFH free serum with or without 
adding back the collected CFH and percentage lysis is assessed. In future work it will be 
important to demonstrate that CFH secreted by RPE cells is active and that its 
concentration in the retina is functionally significant. 
 
ARPE19 cells are heterozygous for the C/T AMD-risk SNP (unpublished data from our 
group) and are therefore ideal to study how the Y/H protein variants may differ in their 
function or secretion. It is not known whether the Y/H CFH variants are secreted at a 
similar level. Over-expression of these variants in human embryonic kidney 293 cells 
(Yu et al., 2007) suggests that this is not the case, however An et al., (2006) report 
enhanced CFH secretion from human RPE genotyped as homozygous for the AMD-
associated H-variant. It would be interesting to study whether one of the variants in 
ARPE19 cells is preferentially secreted at the apical or basal membrane. In order to 
carry out these experiments, Y/H specific CFH antibodies and polarised ARPE19 
monolayers would be required. 
 
Use of an in vitro assay does not allow an investigation into how CFH secretion changes 
with ageing. Gene expression analysis of wild-type mice showed that there was no 
change in Cfh RNA expression from 7-8 weeks to 1 year 4 months suggesting that tight 
regulation of Cfh RNA expression is likely to be important to the health of the retina 
over time. This result is in agreement with similar reports where in mice, Mandal and 
Ayyagari (2006) show no particular transcription pattern in the posterior segment from 
P30-600 and in humans, Hageman et al., (2005) report no change to CFH transcription 
with age. Para-inflammation associated with the ageing of the retina has previously 
been associated with up-regulation of TNFα (Xu et al., 2009), and our data showing 
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that TNFα has no impact on CFH secretion by RPE cells would support the notion that 
there is no change in the regulation of CFH transcription with age and para-
inflammation.  
 
This study overall has attempted to answer some of the questions relating to the 
expression of CFH from the RPE and its function in the retina as a whole. We show that 
RPE cells constitutively secrete CFH de novo at a low level but that this can be 
enhanced by pro-inflammatory cytokines IFN  and IL-1β. We show that the retina is 
reactive to changes in complement regulation and plays on the redundancy between 
complement regulators by compensating for loss of CFH with the up-regulation of DAF 
and CRRY. However, CFH must play a role beyond that which other complement 
regulators can compensate since early signs of photoreceptor degeneration are 
evident in 1 year Cfh-/- retinas.  Overall the phenotype of the 1 year Cfh-/- mice was 
subtle and this may reflect the additional deficiency in these mice which are also low in 
circulating C3. Since patients with AMD have normal circulating levels of C3, it would 
be of interest to generate a RPE-specific Cfh-/- mouse where mice would have normal 
levels of circulating CFH and C3.  The presence of normal levels of circulating C3 may 
attenuate or generate a more severe phenotype in the retina as compared to global 
Cfh-/- mice.  Using the Cfh-/- mouse we were unable to distinguish whether the 
phenotype which developed was due to loss of ocular or systemic CFH, or both. Using 
RPE-specific Cfh gene deletion would allow us to separate the contribution of local as 
compared to systemic CFH to the health of the retina.  This transgenic mouse we are 
currently creating using cre-loxP technology, where a transgenic mouse expressing 
inducible Cre recombinase under the control of the RPE specific monocarboxylate 
transporter 3 gene promoter (Longbottom et al., 2009) is crossed with a transgenic 
mouse expressing floxed Cfh alleles.  
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